Nanox Vision Overview
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and novel digital source. Nanox’s vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically-driven approach. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; Nanox.AI – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE, a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc. that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance its better health outcomes worldwide.
Cumulative Funding Raised Over Time ($)
$26.0MJan 2020
$31.0MJul 2019
$90.0MJul 2020
$110.0MJun 2020
Latest News
growth-positive
Nanox Partners with Monarch to Expand Access to Advanced 3D Imaging
Nano-X Imaging Ltd. has announced a collaboration with Monarch Medical Management to deploy its imaging solutions across various healthcare segments, including workers’ compensation, nursing home facilities, and outpatient clinics. The partnership will initially focus on a dozen proof-of-concept sites before expanding nationwide. The collaboration involves the use of Nanox’s 3D digital tomosynthesis imaging system, Nanox.ARC, and AI-powered software designed to detect early signs of chronic conditions. This partnership marks a significant step in the U.S. expansion of the Nanox.ARC system, as stated by Erez Meltzer, CEO and Acting Chairman of Nano-X.
Partners
growth-positive
Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging
Nano-X Imaging LTD announced a collaboration with Monarch Medical Management and Billing LLC to deploy its advanced imaging solutions across various healthcare segments, including workers compensation, nursing homes, and outpatient clinics. The partnership aims to establish a comprehensive imaging network, initially starting with a proof-of-concept phase at over a dozen sites, with plans for nationwide expansion. This collaboration will provide patients with access to Nanoxs advanced imaging services, including the Nanox.ARC system and AI-powered software for early disease detection. The partnership is seen as a strategic move to enhance patient outcomes and expand Nanoxs presence in the U.S. healthcare market.
Partners
growth-positive
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
Tempus AI has made significant strides in the radiology field by developing advanced AI algorithms and acquiring strategic assets. The company has launched Tempus Pixel, an AI-powered cardiac imaging platform, which recently received FDA 510(k) clearance. This clearance enhances the platforms capabilities in cardiac MR image analysis, providing precise numerical values for cardiac tissue characteristics. Tempus has also strengthened its position through the acquisition of Arterys, integrating its AI tools for imaging data analysis into its platform. The AI in Radiology Market is projected to grow significantly, and Tempus is well-positioned to capitalize on this opportunity.
Product StageAcquisitionFDA approved/pending approval
growth-negative
Nano-X Imaging Second Quarter 2025 Earnings: Misses Expectations
Nano-X Imaging reported a revenue of $3.04 million, marking a 13% increase from the previous year, but still missing analyst estimates by 5%. The company also reported a net loss of $14.7 million, widening by 8.4% from the previous year, and an earnings per share (EPS) miss of 21%. Despite these setbacks, the companys revenue is forecast to grow at an average rate of 51% annually over the next three years, significantly outpacing the 5.9% growth forecast for the US healthcare industry. However, the companys shares have decreased by 3.2% over the past week.
growth-negative
Nano X Imaging Ltd (NNOX) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses ...
Nano X Imaging Ltd reported a net loss of $14.7 million for Q2 2025, an increase from the previous year. Despite revenue growth in teleradiology services, AI solutions revenue remains low. The company is expanding its commercial footprint in the US and Europe, with installations in Romania and Greece. Collaborations with institutions like Duke University aim to enhance clinical education. A multi-year supply agreement has been established to support scalable production. However, high operating expenses and challenges in securing permits in markets like Mexico are delaying expansion. The company does not anticipate break-even in AI solutions until 2026.
CustomersPartnersProduct Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $330M |
| Last funding | $30M |
| Stage | Public |
| Rounds | 6 |
| Investors | 6 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.nanox.vision/ |
| Careers | Careers page |
Locations
Petah Tikva, Israel
Yongin-si, Gyeonggi-do, South Korea
Fort Lauderdale, FL, USA
Photos & Videos
1 item(s)
Nanox Vision Business
Business models
B2G, B2B
Product stage
Beta
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision SupportTarget Customer
Healthcare & Life SciencesMedical Devices IndustryMedical EquipmentHealthcarePatientsProvidersCore Technology
Platforms & InterfacesSoftwareData StorageCloudArtificial IntelligenceTags (15)
healthcare-providersdigital-healthcarex-raydoctorsmedical-image-analysisnanotechnologydiagnostics3d-imagingmedical-devicesartificial-intelligencepatientsimagingcloud-basednon-invasiveearly-detectionNanox Vision Financials
$330M
Total funding
Undisclosed
Capital raised
$30M
Last funding
Public
Funding stage
6
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$26.0MJan 2020
$31.0MJul 2019
$90.0MJul 2020
$110.0MJun 2020
Private Equity Funding
B Round
Jul 2020
$59M
The Yozma Group, SK Ventures, Fujifilm, A-Labs Finance & Advisory, Foxconn Technology Group, Israel Investment Fund Group
B Round
Jun 2020
$20M
SK Ventures (Lead)
B Round
Jan 2020
$26M
Fujifilm, SK Ventures, Foxconn Technology Group
A Round
Jul 2019
$5M
SK Ventures (Lead)
Public Offering / Exit
POEvent
Jul 2023
Undisclosed
POEvent
Aug 2020
Undisclosed
Mergers & Acquisitions
MNAEvent
Aug 2021
$200M
Nanox Vision Lifecycle
Cumulative Funding Raised Over Time
$26.0MJan 2020
$31.0MJul 2019
$90.0MJul 2020
$110.0MJun 2020
All Events
B Round
Jul 2020
$59M
The Yozma Group, SK Ventures, Fujifilm, A-Labs Finance & Advisory, Foxconn Technology Group, Israel Investment Fund Group
B Round
Jun 2020
$20M
SK Ventures (Lead)
B Round
Jan 2020
$26M
Fujifilm, SK Ventures, Foxconn Technology Group
A Round
Jul 2019
$5M
SK Ventures (Lead)
POEvent
Jul 2023
Undisclosed
POEvent
Aug 2020
Undisclosed
MNAEvent
Aug 2021
$200M
Nanox Vision News
214 articles
growth-positive
Nanox Partners with Monarch to Expand Access to Advanced 3D Imaging
Nano-X Imaging Ltd. has announced a collaboration with Monarch Medical Management to deploy its imaging solutions across various healthcare segments, including workers’ compensation, nursing home facilities, and outpatient clinics. The partnership will initially focus on a dozen proof-of-concept sites before expanding nationwide. The collaboration involves the use of Nanox’s 3D digital tomosynthesis imaging system, Nanox.ARC, and AI-powered software designed to detect early signs of chronic conditions. This partnership marks a significant step in the U.S. expansion of the Nanox.ARC system, as stated by Erez Meltzer, CEO and Acting Chairman of Nano-X.
Partners
growth-positive
Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging
Nano-X Imaging LTD announced a collaboration with Monarch Medical Management and Billing LLC to deploy its advanced imaging solutions across various healthcare segments, including workers compensation, nursing homes, and outpatient clinics. The partnership aims to establish a comprehensive imaging network, initially starting with a proof-of-concept phase at over a dozen sites, with plans for nationwide expansion. This collaboration will provide patients with access to Nanoxs advanced imaging services, including the Nanox.ARC system and AI-powered software for early disease detection. The partnership is seen as a strategic move to enhance patient outcomes and expand Nanoxs presence in the U.S. healthcare market.
Partners
growth-positive
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
Tempus AI has made significant strides in the radiology field by developing advanced AI algorithms and acquiring strategic assets. The company has launched Tempus Pixel, an AI-powered cardiac imaging platform, which recently received FDA 510(k) clearance. This clearance enhances the platforms capabilities in cardiac MR image analysis, providing precise numerical values for cardiac tissue characteristics. Tempus has also strengthened its position through the acquisition of Arterys, integrating its AI tools for imaging data analysis into its platform. The AI in Radiology Market is projected to grow significantly, and Tempus is well-positioned to capitalize on this opportunity.
Product StageAcquisitionFDA approved/pending approval
growth-negative
Nano-X Imaging Second Quarter 2025 Earnings: Misses Expectations
Nano-X Imaging reported a revenue of $3.04 million, marking a 13% increase from the previous year, but still missing analyst estimates by 5%. The company also reported a net loss of $14.7 million, widening by 8.4% from the previous year, and an earnings per share (EPS) miss of 21%. Despite these setbacks, the companys revenue is forecast to grow at an average rate of 51% annually over the next three years, significantly outpacing the 5.9% growth forecast for the US healthcare industry. However, the companys shares have decreased by 3.2% over the past week.
growth-negative
Nano X Imaging Ltd (NNOX) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses ...
Nano X Imaging Ltd reported a net loss of $14.7 million for Q2 2025, an increase from the previous year. Despite revenue growth in teleradiology services, AI solutions revenue remains low. The company is expanding its commercial footprint in the US and Europe, with installations in Romania and Greece. Collaborations with institutions like Duke University aim to enhance clinical education. A multi-year supply agreement has been established to support scalable production. However, high operating expenses and challenges in securing permits in markets like Mexico are delaying expansion. The company does not anticipate break-even in AI solutions until 2026.
CustomersPartnersProduct Stage
Nanox Announces Second Quarter of 2025 Financial Results and Provides Business Update
growth-positive
Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025
Nano-X Imaging LTD, an innovative medical imaging technology company, announced it will report its financial results for the quarter ended June 30, 2025, on August 12, 2025. The company, listed on NASDAQ as NNOX, focuses on preventive healthcare through affordable medical imaging technologies utilizing advanced AI and proprietary digital X-ray sources. Nanoxs offerings include the Nanox.ARC system, Nanox.AI algorithms, Nanox.CLOUD platform, and Nanox.MARKETPLACE. These solutions aim to improve early detection and treatment, enhancing health outcomes globally. The company will host a conference call to discuss the results and provide a business update.
growth-positive
The Zacks Analyst Blog Highlights Taiwan Semiconductor Manufacturing, NVIDIA, Apple, Advanced Micro Devices, Broadcom and Intel
Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) reported a record surge in second-quarter profits, driven by strong demand for AI chips and advanced semiconductor nodes. The companys net income increased by 60.7% year over year, with revenues rising 38.7% to NT$933.80 billion. TSMCs high-performance computing division, which includes AI and 5G applications, contributed significantly to this growth. The company projects third-quarter revenues to increase further, driven by demand from major clients like NVIDIA and Apple. TSMCs stock has outperformed the industry, reflecting its market dominance and pricing power. The company expects a 30% revenue surge in 2025, highlighting its strong position in the semiconductor industry.
Customers
growth-positive
The Zacks Analyst Blog Highlights NVIDIA, SoundHound, Microsoft, Apple, Intel and Advanced Micro Devices
NVIDIA Corp. has achieved significant growth, with its market cap reaching nearly $4 trillion, driven by advancements in artificial intelligence (AI) and the popularity of its CUDA software platform. Despite challenges such as competition from DeepSeeks cost-effective language model and geopolitical issues like tariffs, NVIDIAs shares have risen by 24% over the past year. The company has successfully delivered its Blackwell chips, resulting in a 69% increase in sales to $44.1 billion in the fiscal first quarter. Meanwhile, SoundHound AI, Inc. has also experienced substantial growth, with its share price surging by 211.6% over the past year, driven by increasing demand for its voice AI solutions.
Customers
growth-positive
Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC
Nano-X Imaging LTD has announced a partnership with Keiser University to deploy its advanced 3D imaging system, Nanox.ARC, at the universitys Sarasota Campus. This collaboration aims to enhance the clinical educational program by providing students and healthcare professionals with access to cutting-edge imaging technology. The Nanox.ARC system offers superior diagnostic performance with reduced radiation exposure compared to traditional methods. This partnership is part of Nanoxs mission to promote preventive healthcare through innovative technology. The collaboration is expected to increase the usage of Nanox.ARCs clinical protocols and improve patient care outcomes.
Partners
growth-positive
Q2 Virtual Investor Summit: Presentations Available Now
TEN Holdings Inc. is developing a new SaaS platform aimed at streamlining and scaling virtual and hybrid events for enterprise clients. The company is also pursuing a roll-up strategy to acquire complementary event tech and service companies, aiming to build a market-leading, all-in-one solution. This strategic focus indicates a growth-positive impact on the company as it expands its offerings and market presence. The Investor Summit provided a platform for TEN Holdings to present its innovations and future plans to potential investors and partners.
AcquisitionProduct Stage
growth-positive
Sidoti Events, LLC's Virtual June Small-Cap Conference
Sidoti & Company, LLC, through its affiliate Sidoti Events, LLC, is hosting a two-day June Small-Cap Conference on June 11-12, 2025. The conference is part of Sidotis strategy to expand its rapidly growing conference business, which focuses on small and microcap companies. Sidoti has a strong presence in the securities research sector, covering approximately 150 equities, with a significant portion participating in its Company Sponsored Research program. The company also established Lighthouse Equity Research to cater to companies facing challenges in obtaining coverage. Sidoti Events benefits from Sidotis extensive network of institutional relationships, providing valuable corporate access through multiple investor conferences annually.
growth-positive
Nanox Imaging to Present at the Investor Summit Virtual on June 10, 2025
Nanox Imaging, a company focused on affordable medical imaging technologies, announced that its CFO, Ran Daniel, will present at the Investor Summit Virtual on June 10, 2025. The company, listed on NASDAQ as NNOX, aims to drive the transition to preventive healthcare using advanced AI and proprietary digital X-ray sources. The Investor Summit is an exclusive event for investors interested in small and microcap stocks, providing opportunities to engage with management and learn from experts. The event highlights companies that are undervalued and have potential catalysts for growth.
Management Changes
growth-positive
Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for Spine Assessment
Nano-X Imaging LTD, through its subsidiary Nanox AI Ltd, has received EU MDR CE mark certification for its HealthOST software, a tool for bone health analysis. This certification allows for the commercialization of HealthOST across Europe, ensuring compliance with high regulatory standards. HealthOST, which leverages AI technology, provides automated quantification of vertebral parameters from routine CT scans to support the evaluation of musculoskeletal diseases like osteoporosis. The software builds on its previous FDA 510(k) clearance received in April 2022. With osteoporosis being a significant health issue in Europe, the software aims to aid in early detection and preventive care, potentially reducing healthcare costs associated with osteoporotic fractures.
Product StageFDA approved/pending approval
growth-positive
Nanox to Participate in Sidoti Small Cap Conference
Nano-X Imaging LTD, a medical imaging technology company, announced its participation in the Sidoti Small Cap Conference scheduled for June 11-12, 2025. The company will present on June 11, focusing on its innovative solutions in preventive healthcare. Nanox aims to expand the reach of its technology, which includes AI-enhanced imaging systems and a cloud-based platform for data management. The companys ecosystem features products like Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all designed to improve early detection and treatment of diseases. This participation is seen as a positive step for the companys growth and visibility in the industry.
growth-negative
What Does The Future Hold For Nano-X Imaging Ltd. (NASDAQ:NNOX)? These Analysts Have Been Cutting Their Estimates
Nano-X Imaging Ltd. (NASDAQ:NNOX) has experienced a significant downgrade in analyst estimates, leading to a negative outlook for the company. Analysts have reduced their revenue forecasts from $23 million to $14 million for 2025, while also increasing the expected loss per share from $0.73 to $0.79. This has resulted in a 17% decrease in the consensus price target to $9.75. Despite the downgrade, Nano-X Imaging is still expected to grow faster than the wider industry, with a forecasted 27% annual growth rate compared to the industrys 6.7%. The changes in estimates have led to increased pessimism about the companys intrinsic value.
growth-negative
Nano-X Imaging First Quarter 2025 Earnings: Misses Expectations
Nano-X Imaging reported a revenue of $2.82 million, marking a 10% increase from the previous quarter, but still missing analyst estimates by 29%. The company also reported a net loss of $13.2 million, with a loss per share of $0.21, which missed analyst estimates by 9.1%. Despite the current financial setbacks, the company is forecasted to grow its revenue by 51% annually over the next three years, significantly outpacing the 6.7% growth forecast for the US healthcare industry. However, the companys shares have fallen by 8.4% over the past week. The article highlights the potential of AI in healthcare, with Nano-X Imaging being one of the companies involved.
growth-negative
Nano-X Imaging price target lowered to $7 from $9 at Alliance Global Partners
Alliance Global Partners has lowered the price target for Nano-X Imaging from $9 to $7 while maintaining a Buy rating on the shares. This decision is attributed to the companys Q1 revenue missing forecasts, which is indicative of a challenging macroeconomic environment. Despite the revenue miss, Nano-X Imaging has reported FDA clearance, which is a positive development. The article highlights the companys financial performance and the implications of the macro environment on its stock valuation.
growth-positive
Nano X Imaging Ltd (NNOX) Q1 2025 Earnings Call Highlights: Strategic Growth Amidst Financial ...
Nano X Imaging Ltd (NASDAQ:NNOX) reported a revenue increase to $2.8 million for Q1 2025, up from $2.6 million in Q1 2024, despite a net loss of $13.2 million. The company has made strategic acquisitions, including USARAD and Zebra Medical Imaging, which have helped double revenues and transition Nanox.AI to a revenue-generating business. Nano X Imaging has received FDA 510(k) clearance for its Nanox.ARC-X system and plans to deploy over 100 ARC systems globally by the end of 2025. The company is experiencing steady growth in its US teleradiology business and increasing revenues from AI solutions, although it faces challenges with regulatory and setup delays.
AcquisitionFDA approved/pending approvalExpand
growth-positive
Nanox Announces First Quarter 2025 Financial Results and Provides Business Updates
Nano-X Imaging LTD announced its first-quarter results for 2025, reporting a revenue increase to $2.8 million from $2.6 million in the same period of 2024. The company received 510(k) clearance from the FDA for its Nanox.ARC X system, marking a significant milestone. Nano-X has signed multiple commercial agreements to market its Nanox.ARC and Nanox.AI solutions, with over 60 units in various stages of implementation. The company continues to generate revenue through teleradiology services and aims to expand its reach by collaborating with medical imaging and AI companies. Despite a net loss increase to $13.2 million, the companys strategic efforts are focused on accelerating the deployment of its technologies.
Product StageCustomersPartners
growth-positive
Nanox to Report First Quarter 2025 Financial Results on May 22, 2025
Nano-X Imaging LTD, a medical imaging technology company, announced it will report its financial results for Q1 2025 on May 22, 2025. The company, listed on NASDAQ as NNOX, focuses on advancing preventive healthcare through affordable medical imaging technologies leveraging AI and a proprietary digital X-ray source. Nanox aims to expand its technologys reach beyond hospital settings, offering solutions from scan to diagnosis. The companys ecosystem includes Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, which collectively enhance early detection and treatment to improve health outcomes globally. A conference call hosted by CEO Erez Meltzer and CFO Ran Daniel will provide further business updates.
growth-positive
Nano X Imaging Ltd (NNOX) Q4 2024 Earnings Call Highlights: Navigating Growth Amidst Financial ...
Nano X Imaging Ltd (NASDAQ:NNOX) reported a net loss of $14.1 million for Q4 2024, an increase from the previous year. Despite this, the company achieved significant regulatory milestones, including FDA clearance and CE mark designation for its Nanox.ARC system. The company is expanding its market presence in the US and Europe through new distribution agreements and strategic partnerships. Positive feedback from initial customers and early adopters indicates strong market interest. Nano Xs AI solutions are gaining traction with new customer engagements. However, revenue from AI solutions remains low, and there is uncertainty about the timing of significant revenue growth. Operating expenses have increased, particularly in general and administrative costs.
Product StageCustomersPartners
growth-positive
Nanox New Imaging System Receives FDA Clearance
Nano-X Imaging Ltd. announced that its multi-source digital imaging system, Nanox.ARC X, has received FDA 510(k) clearance for general use. This clearance marks a significant advancement in their imaging technology, allowing for easier adoption of digital 3D imaging by healthcare providers. The Nanox.ARC X features a simplified installation process and supports remote software upgrades. The company plans to expand its product portfolio by offering the Nanox.ARC X later this year alongside the existing Nanox.ARC.
Product StageFDA approved/pending approvalExpand
growth-positive
Why Nano-X Imaging Stock Soared Today
Nano-X Imaging, an Israeli X-ray imaging company, has received FDA clearance for its Nanox.ARC X technology, which uses artificial intelligence to produce 3D tomographic images. This approval marks a significant milestone for the company, which aims to disrupt the medical devices market with a unique business model that charges per X-ray delivered. Despite being unprofitable with significant cash burn, the company is poised for growth if it can demonstrate demand for its services. Analysts predict profitability by 2028, but the company must generate cash flow soon to sustain operations.
Product StageFDA approved/pending approval
growth-positive
Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X
Nano-X Imaging LTD has received FDA 510(k) clearance for its new multi-source digital tomosynthesis system, the Nanox.ARC X. This system is designed to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal, and paranasal indications. The Nanox.ARC X features a streamlined design with a smaller footprint and a simplified installation process, making it more accessible to healthcare settings with space constraints. The system allows for remote software upgrades and new capabilities following future regulatory clearances. This FDA clearance marks a significant milestone for Nano-X Imaging, advancing its mission to expand access to essential medical imaging technology.
FDA approved/pending approval
growth-negative
Nano-X Imaging Full Year 2024 Earnings: Misses Expectations
Nano-X Imaging reported a revenue of US$11.3 million, marking a 14% increase from FY 2023. However, the company also reported a net loss of US$53.5 million, which is a 12% improvement from the previous fiscal year. Despite these improvements, the companys revenue and earnings per share missed analyst estimates by 5.1% and 2.2%, respectively. Looking forward, the company forecasts a 44% annual growth in revenue over the next three years, significantly outpacing the 7.2% growth forecast for the US Healthcare industry. Despite these optimistic projections, the companys shares have fallen by 18% over the past week.
growth-positive
Q4 2024 Nano-X Imaging Ltd Earnings Call
Nano-X Imaging Ltd has reported significant progress in its operations, marked by regulatory successes, including FDA clearance and CE mark certification for its Nanox.ARC system. The company is expanding its market presence in the US and Europe, with new customer acquisitions and partnerships. Nano-X is also advancing its AI technology, with new collaborations in the US healthcare market. The company is focused on expanding its sales and clinical support teams to support its growing customer base. Clinical trials are underway to further validate the Nanox.ARC technology, and the company is actively working on strategic partnerships to enhance its supply chain and market reach.
Product StageCustomersPartnersFDA approvedExpand
Nanox Announces Fourth Quarter of 2024 Financial Results and Provides Business Updates
growth-positive
Nano-X Imaging (NNOX) Q4 2024 Earnings Call Transcript
Nano-X Imaging reported significant progress in its Q4 2024 earnings call, highlighting regulatory achievements and market expansion. The company received FDA clearance for its Nanox.ARC system and CE Mark certification for the European market. These milestones are expected to accelerate commercialization efforts. Nano-X is expanding its U.S. presence with new channel partners and has entered the European market. The company is also advancing its AI solutions, securing new customers and partnerships. Financially, Nano-X reported increased revenue from teleradiology services and AI solutions, despite a net loss. The company is focused on expanding its sales and clinical support teams to meet growing demand.
Product StageCustomersPartnersFDA approvedExpand
growth-positive
Nano-X Imaging (NNOX) Presents AI Bone Health Data at Top Conferences
Nano-X Imaging Ltd. (NASDAQ:NNOX) is highlighted in a discussion about the global AI industrys rapid growth and potential challenges due to new US export controls on AI processors. The AI diffusion rule, effective May 15th, aims to concentrate AI development within the US and its allies, potentially disrupting global infrastructure plans. Nano-X Imaging, which offers AI-powered medical imaging technologies, is positioned against other AI companies in terms of hedge fund interest. The company provides affordable imaging solutions with AI-enhanced CT readings and a cloud-based data management platform. The article suggests that the US policy could impact global AI development, with industry leaders urging a reassessment of the strategy.
growth-positive
Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe
Nano-X Imaging LTD, through its subsidiary Nanox AI, has announced findings from the ADOPT study, which highlights the role of its AI-enabled medical imaging analytics in enhancing fracture detection and reducing healthcare costs. The study, conducted at four NHS trusts in the UK, demonstrated that the AI tool HealthVCF identified significantly more vertebral compression fractures than the national average. The study also showed a reduction in patient refracture rates and cost savings for healthcare organizations. A newer version of the AI tool, HealthOST, has been FDA-cleared and offers improved precision in fracture measurement and bone density assessment. These findings will be presented at major medical conferences, emphasizing the potential of AI in improving bone health assessment and patient care.
Product StageCustomers
growth-positive
Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025
Nano-X Imaging LTD, a medical imaging technology company, announced it will report its financial results for the quarter and fiscal year ended December 31, 2024. The announcement will be made on March 31, 2025, before the market opens. The company, listed on NASDAQ as NNOX, is focused on advancing preventive healthcare through affordable medical imaging technologies that leverage AI and proprietary digital X-ray sources. Nanox aims to expand the reach of its technology beyond hospitals, offering solutions from scanning to diagnosis. The Nanox ecosystem includes products like Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, which collectively aim to improve early detection and treatment for better health outcomes globally.
growth-positive
Nanox.ARC Imaging System Granted Certification in EU
Nano-X Imaging Ltd. announced that its digital multi-source 3D tomosynthesis imaging system, Nanox.ARC, has received CE mark certification for the European market. This certification, along with FDA clearance for general use in the U.S., marks a significant milestone in the companys global expansion efforts. The CE mark allows Nano-X to accelerate the commercial introduction of Nanox.ARC across Europe, potentially offering shorter waiting times and more efficient diagnosis for patients. The company is also pursuing strategic partnerships to enhance its market presence.
Product StageFDA approved/pending approvalPartners
growth-positive
Nanox to Present New Clinical Data on Nanox.ARC Advanced 3D Digital Tomosynthesis Imaging System at ECR 2025
Nano-X Imaging LTD has announced that its Nanox.ARC digital tomosynthesis system has received CE mark certification, allowing it to be marketed in Europe. This follows the FDA 510(k) clearance received in December 2024, marking significant progress in the global commercialization of the system. The Nanox.ARC has demonstrated enhanced capabilities in musculoskeletal imaging and lung nodule detection, outperforming standard X-rays. The company will present supporting data at the 2025 European Congress of Radiology. These developments highlight Nano-Xs commitment to advancing patient care through innovative medical imaging technology.
Product StageFDA approved/pending approval
growth-positive
Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market
Nano-X Imaging LTD has achieved a significant milestone by receiving the CE Mark certification for its Nanox.ARC imaging system, following its recent FDA clearance in the U.S. This regulatory approval allows the company to market its advanced digital multi-source 3D tomosynthesis imaging system in Europe. The Nanox.ARC system, which includes the Nanox.CLOUD infrastructure, represents a major advancement in X-ray technology, offering enhanced visualization through a comprehensive three-dimensional view. This development is expected to accelerate the commercial introduction of Nanox.ARC across Europe and support the companys global expansion efforts. The system is intended for use in professional healthcare facilities and is designed to integrate seamlessly into existing clinical workflows.
Product StageFDA approved/pending approval
growth-negative
Does Nvidia Know Something Wall Street Doesn't? The Chipmaker Just Sold 4 Popular Artificial Intelligence (AI) Stocks and Bought 2 Others.
Nvidia, a leader in AI and chipmaking, recently made significant adjustments to its investment portfolio, selling stakes in several AI-focused companies due to perceived stretched valuations. The company sold its entire positions in SoundHound AI, Serve Robotics, and Nano-X Imaging, while trimming its stake in Arm Holdings. Nvidia also added new positions in Nebius Group and WeRide, indicating a strategic shift towards potentially undervalued opportunities. These moves reflect Nvidias response to market valuations and its pursuit of more promising investments. The companys actions suggest a focus on optimizing its portfolio for future growth in the AI sector.
AcquisitionInvestment
growth-positive
These Tech Stocks Soared Friday After Nvidia Disclosed Stakes
Shares of WeRide, a Chinese autonomous driving company, surged after Nvidia disclosed a stake in the company. Nvidias filing revealed it held 1.74 million shares of WeRide as of December 31, leading to an 80% increase in WeRides stock value. WeRide, which operates driverless vehicles in 30 cities across nine countries, recently debuted on the Nasdaq in October. Nvidia also invested in Nebius Group, an AI infrastructure company, while divesting from SoundHound AI, Serve Robotics, and Nano-X Imaging. Nvidia reduced its stake in Arm Holdings. The article highlights Nvidias strategic investment moves and their impact on the stock market.
InvestmentPublic Trading
growth-negative
Nvidia's Portfolio Shake-Up: SoundHound, Serve Robotics Drop as WeRide Surges
Nvidia recently announced a significant reshuffle of its investment portfolio, selling off stakes in SoundHound AI, Serve Robotics, and Nano-X Imaging. This decision led to a sharp decline in the stock prices of these companies. Nvidia also reduced its stake in Arm Holdings by 44% but continues to hold shares in Applied Digital, Nebius, and Recursion Pharmaceuticals. Additionally, Nvidia made a new investment in the Chinese self-driving startup WeRide, acquiring 1.7 million shares, which caused WeRides stock to surge. Nvidias actions reflect a strategic shift in its investment focus, impacting the market performance of the involved companies.
Investment
growth-negative
Why SoundHound AI, Serve Robotics, and Nano-X Imaging Are Getting Crushed Today (Hint: It Has to Do With Nvidia)
Shares of several AI companies, including SoundHound AI, Serve Robotics, and Nano-X Imaging, fell sharply after Nvidia disclosed it exited its investment positions in these companies. Nvidia had previously invested in these firms, likely due to potential partnerships or to grow the AI market. Despite the exit, Nvidias partnerships with SoundHound AI and Serve Robotics remain intact. SoundHound AI, which develops AI-powered voice solutions, has seen significant stock growth over the past year. However, none of the companies have turned a profit yet, making them volatile investments. Nvidias exit may not necessarily reflect the companies potential, as the reason for the sale remains unclear.
PartnersInvestment
growth-positive
When Can We Expect A Profit From Nano-X Imaging Ltd. (NASDAQ:NNOX)?
Nano-X Imaging Ltd. is on the verge of a significant milestone as it approaches breakeven. The company, which develops a commercial-grade tomographic imaging device, has reduced its losses from $61 million to $50 million. Analysts predict that Nano-X Imaging will achieve profitability by 2027, with an anticipated annual growth rate of 60%. The company has managed its capital effectively, maintaining a low debt level of 2.1% of equity, which minimizes investment risk. While the article provides a high-level overview, it highlights the companys potential for growth and the importance of its management team in steering towards profitability.
growth-negative
Nano-X Imaging Ltd. (NNOX): AI-Powered Medical Imaging Innovations
The article discusses the position of Nano-X Imaging Ltd. among AI companies with a market cap under $2 billion. It highlights the potential and risks associated with AI, such as customer concentration and market volatility. Concerns are raised about the semiconductor market, particularly regarding NVDA and the demand for high-end chips potentially shifting to smaller companies. The article also touches on broader market performance, economic data, and hedge fund sentiment towards AI stocks. The methodology involves analyzing hedge fund interest in small-cap and large-cap stocks, with a strategy that has outperformed the market since 2014.
growth-positive
Are Business Services Stocks Lagging NanoX Imaging (NNOX) This Year?
Nano-X Imaging Ltd. (NNOX) is performing well within the Business Services sector, with a Zacks Rank of #2 (Buy) and a year-to-date return of 23.2%, outperforming the sector average of 20.2%. The companys earnings outlook has improved, with a 1.6% increase in the Zacks Consensus Estimate for full-year earnings over the past 90 days. Although NNOX is slightly underperforming its Technology Services industry, which has gained an average of 53.2% this year, it remains a strong performer. Investors are advised to keep an eye on Nano-X Imaging Ltd. and VerifyMe, Inc. for continued solid performance.
growth-positive
Nano-X Imaging Expands FDA Clearance for Nanox.ARC
Nano-X Imaging has announced that its Nanox.ARC system has received FDA clearance for expanded use, including pulmonary and intra-abdominal imaging. This development enhances the systems capabilities beyond its initial musculoskeletal applications. The Nanox.ARC, now operational in seven U.S. states, is designed to provide cost-effective and advanced diagnostic imaging solutions, potentially transforming patient care by reducing wait times and integrating seamlessly into healthcare facilities. This FDA clearance is a significant milestone for Nano-X Imaging, indicating a positive growth trajectory as it broadens its market reach and application scope.
growth-positive
Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication
Nano-X Imaging LTD has received FDA clearance for its Nanox.ARC system to produce tomographic images for general use, expanding its capabilities beyond the musculoskeletal system to include pulmonary, intra-abdominal, and paranasal sinus indications. This clearance allows the company to offer broader imaging capabilities to U.S. healthcare providers, enhancing patient care with advanced diagnostic imaging. The Nanox.ARC, which uses innovative digital X-ray technology, is already deployed in healthcare facilities across seven U.S. states and is expected to expand further. The Diagnostic Radiology Institute of Kansas City is one of the facilities benefiting from this technology, which aims to improve diagnostic capabilities and patient experience.
Customers
growth-positive
Here's Why Nanox Stock Went Up Today
Nano-X Imaging, a medical imaging company, experienced a rise in its stock price following the announcement of expanded regulatory clearance from the U.S. Food and Drug Administration (FDA) for its flagship device, the Nanox.ARC. This clearance now includes pulmonary and intra-abdominal imaging, marking a significant step towards the companys goal of generating recurring revenue from its medical imaging software. Despite this positive development, the company remains in an early stage with a long path to profitability, as evidenced by its recent quarterly revenue of $3 million. Investors are advised to be cautious due to potential volatility and the possibility of substantial losses.
growth-positive
Nanox.ARC Gets FDA Clearance for Expanded Diagnostic Imaging
Nanox (Nasdaq: NNOX) has received FDA clearance to produce tomographic images for broader diagnostic applications. The companys Nanox.ARC system, which is already deployed in healthcare facilities across seven U.S. states, uses proprietary tomosynthesis technology with a cold cathode to deliver detailed 3D imaging. This advancement improves visualization and reduces the limitations of traditional 2D X-rays. According to Erez Meltzer, Nanoxs CEO and Acting Chairman, this FDA clearance allows the company to offer U.S. healthcare providers significantly broader imaging capabilities, enhancing patient care with a cost-effective solution.
growth-negative
Nano-X Imaging Ltd. (NNOX): A Bear Case Theory
Nano-X Imaging Ltd. reported mixed Q3 2024 results, with revenue increasing to $3 million from $2.5 million in Q3 2023. The company expanded its U.S. sales and support teams and secured new distribution agreements with SpinexMedical, Corewell Health, Dandelion Health, and Oxford University Hospitals. Despite these positive developments, Nano-X faced significant financial challenges, with cash reserves dropping from $82.8 million to $57.1 million and a net loss of $13.6 million. The company struggled with slow deployments of its Nanox.ARC systems, raising concerns about its ability to meet promises. Revenue from imaging devices was notably low, and transparency issues regarding system deployments were highlighted.
CustomersPartnersExpand
growth-negative
Nano-X Imaging price target lowered to $11 from $12 at Alliance Global Partners
Alliance Global Partners has lowered its price target for Nano-X Imaging from $12 to $11, while maintaining a Buy rating on the companys shares. This decision follows the companys Q3 report, where overall revenue exceeded expectations, but the performance of the key Imaging systems line fell short. Despite the reduction in near-term revenue targets for Imaging systems, the firm has kept its peak revenue forecasts intact. The article highlights the financial progress of Nano-X Imaging, including a reduction in quarterly EPS loss compared to the previous year.
growth-positive
Nano-X Imaging Third Quarter 2024 Earnings: Misses Expectations
Nano-X Imaging reported a revenue of $3.03 million for the trailing 12-month period, marking a 22% increase from the third quarter of 2023. Despite a net loss of $13.6 million, the loss narrowed by 36% compared to the previous quarter. The companys earnings per share (EPS) improved from a loss of $0.38 to $0.23. However, both revenue and EPS missed analyst estimates by 14% and 6.2%, respectively. Looking forward, the companys revenue is expected to grow at an average rate of 49% annually over the next three years, significantly outpacing the 6.6% growth forecast for the US healthcare industry. Nano-X Imagings shares have risen by 8.7% over the past week. The article highlights the companys financial performance and future growth prospects.
growth-positive
Q3 2024 Nano-X Imaging Ltd Earnings Call
Nano-X Imaging Ltd held its third-quarter 2024 earnings call, highlighting significant progress in deploying its Nano-X ARC technology and Nano-X AI solutions. The company has expanded its presence in the US, with deployments across seven states and plans to double its sales and service personnel by the end of 2025. Nano-X has signed new deals with prestigious institutions like Oxford University Hospitals in the UK and continues to advance its regulatory efforts with the US FDA and European bodies. The company reported $2.6 million in revenue from its USARAD business and anticipates further growth. Nano-X AI was recognized in Times Best Inventions of 2024, and the company is actively expanding its global footprint and strategic partnerships.
CustomersPartnersExpand
growth-negative
Nano X Imaging Ltd (NNOX) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
Nano X Imaging Ltd reported a GAAP net loss of $13.6 million for Q3 2024, highlighting ongoing financial challenges. Despite a gross loss of $2.8 million, the company has made strides in market expansion by deploying 47 units of its Nano-X ARC technology and doubling its sales and service personnel in the US. The company signed new partnerships, including with Oxford University Hospitals, and generated $2.6 million in revenue from its USARAD business. However, revenue from imaging systems was only $29,000, indicating monetization difficulties. Nano X is actively seeking regulatory approvals, which are crucial for its market expansion and revenue growth.
CustomersPartnersExpand
growth-positive
Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update
Nano-X Imaging LTD reported a positive third quarter of 2024, with revenue increasing to $3.0 million from $2.5 million in the same period of 2023. The company expanded its US sales and support teams and deployed numerous units globally. It signed new distribution agreements with SpinexMedical and extended agreements with Corewell Health, Dandelion Health, and Oxford University Hospitals. A multi-site clinical trial is underway in Israel and Ghana to support the clinical value of Nanox.ARC. The company is working with the FDA and European Union regulatory bodies to secure approvals, which are expected to expand its market reach. Despite a net loss of $13.6 million, this marks an improvement from the previous years loss, attributed to reduced expenses related to goodwill impairment.
CustomersPartnersExpand
growth-positive
Nano-X Imaging (NNOX) Q3 2024 Earnings Call Transcript
Nano-X Imaging reported its Q3 2024 earnings, highlighting significant progress in deploying its Nanox.ARC technology. The company has deployed 47 units across the U.S. and is expanding its sales and support teams to enhance its market presence. Nano-X is also advancing its regulatory efforts with the FDA and European Union for additional clearances. The company signed new partnerships, including with Oxford University Hospitals in the U.K., and its AI solutions were recognized in Times Best Inventions of 2024. The teleradiology business generated $2.6 million in revenue, a quarterly record. Nano-X is focused on expanding its footprint and enhancing its technology to drive growth.
CustomersPartnersExpand
growth-positive
Nanox to Report Third Quarter and Financial Results on November 21, 2024
Nano-X Imaging LTD, a medical imaging technology company, announced it will release its financial results for the quarter ending September 30, 2024, on November 21, 2024. The announcement will be followed by a conference call hosted by CEO Erez Meltzer and CFO Ran Daniel to discuss the results and provide a business update. The company focuses on preventive healthcare through affordable imaging technologies, leveraging AI for diagnostics. Its ecosystem includes products like Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, aimed at improving early detection and treatment. The announcement is expected to positively impact the companys growth by highlighting its innovative solutions and market presence.
growth-positive
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI Solutions
Nano-X Imaging LTD, a medical imaging technology company, announced that its subsidiary, Nanox AI, received a Special Mention in TIMEs Best Inventions of 2024 list. This recognition highlights Nanox AIs innovative use of AI to detect asymptomatic chronic conditions early through routine CT scans. The solutions have received FDA 510(k) clearance and focus on cardiac, bone, and liver health. This accolade underscores Nanoxs commitment to improving patient outcomes through early detection and preventive care. The announcement is a positive development for the company, enhancing its reputation in the medical imaging field.
growth-positive
Nanox to Participate in Upcoming Investor Conference in September 2024
Nano-X Imaging LTD, an innovative medical imaging technology company, announced its participation in the Cantor Fitzgerald Global Healthcare Conference in September 2024. The companys CEO, Erez Meltzer, and CFO, Ran Daniel, will engage in a fireside chat on September 18, 2024. The event will be accessible via a live webcast. Nanox aims to make diagnostic medicine more accessible and affordable through its proprietary technology, including the Nanox.ARC system, AI-based algorithms, cloud infrastructure, and a teleradiology services platform. The participation in the conference is expected to positively impact the companys growth by attracting potential investors.
Investment
growth-positive
Nano-X Imaging Ltd. (NNOX): An Under The Radar AI Stock You Should Pay Attention To
Nano-X Imaging Ltd. (NASDAQ:NNOX) is gaining attention for its AI-integrated diagnostic imaging solutions. The company has developed a cost-effective, efficient tomographic imaging device and an AI system called NanoxAI, which aids in interpreting patient scans and detecting chronic conditions early. With FDA approval and a vast database of patient records, Nano-X is poised for significant sales growth. Wall Street analysts, including Alliance Global Partners, have given the stock a Buy rating, highlighting its potential for profitability through AI-based systems and per-scan revenue. The company ranks 20th among under-the-radar AI stocks, attracting hedge fund interest.
CustomersInvestment
growth-positive
Nano-X Imaging Ltd. (NNOX): This AI Stock Could Go Parabolic According to Financial Media
Nano-X Imaging Ltd. (NASDAQ:NNOX) is highlighted as a promising AI stock, particularly in the field of medical imaging. The company has developed a commercial-grade tomographic imaging device that is smaller, cheaper, and more efficient than traditional X-ray machines. Nano-X has also integrated AI into its diagnostics, with FDA-approved uses for reading patient scans and identifying chronic conditions early. The company is attracting attention from Wall Street analysts, with Alliance Global Partners recently giving it a Buy rating and a $12 price target. The firm uses a vast database for its AI-based health solutions and expects sales to ramp up in the coming quarters.
CustomersInvestment
growth-positive
NANO-X IMAGING LTD (NNOX): A Penny Stock That Will Make You a Millionaire
NANO-X IMAGING LTD (NASDAQ:NNOX) is highlighted as a promising penny stock in the healthcare sector, particularly due to its innovative tomographic imaging device and AI solutions. The company has garnered attention from notable investors like Steve Cohen, Cathy Wood, and Ken Griffin, each investing around $3 million. Analysts expect the stock to rise by 122.2%, partly due to its partnership with AI-giant NVIDIA. The company generated $113,000 in revenue in the second quarter from its AI solutions. Overall, NANO-X IMAGING LTD is considered a high-potential investment, especially in the context of a potential rate cut by the Fed, which could benefit smaller companies.
InvestmentPartnersCustomers
growth-positive
Nanox’s Upgraded AI Cardiac Solution Receives FDA Clearance
Nano-X Imaging Ltd. announced that it has received clearance from the FDA for HealthCCSng V2.0, an upgraded version of its AI cardiac solution. The new version includes features such as zero calcium categorization and a numerical calcium score, which help predict future cardiovascular incidents. This advancement aims to bridge the gap between radiology and cardiology by providing a unified approach to assessing imaging data. The companys CEO, Erez Meltzer, highlighted the significance of this development in enhancing medical imaging and patient care.
growth-positive
Here's Why NanoX Imaging (NNOX) Could be Great Choice for a Bottom Fisher
Nano-X Imaging Ltd. (NNOX) has experienced a bearish trend, with its stock losing 19.7% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session suggests a potential trend reversal, indicating that bulls might have gained control over the price. Additionally, strong agreement among Wall Street analysts in raising earnings estimates for NNOX enhances the prospects of a trend reversal. The company currently holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks ranked by Zacks Investment Research, further supporting a positive outlook for the stock.
growth-positive
Are Business Services Stocks Lagging ICF International (ICFI) This Year?
ICF International (ICFI) is outperforming its peers in the Business Services sector, according to Zacks Investment Research. The companys year-to-date performance is better than the sector average, with a gain of about 19% compared to the sectors average return of 10.6%. ICFIs full-year earnings estimate has also moved 4.5% higher over the past three months, indicating a stronger analyst sentiment and improving earnings outlook. The company currently has a Zacks Rank of #2 (Buy).
Investment
Growth-Negative
Nano-X Imaging Second Quarter 2024 Earnings: Misses Expectations
Nano-X Imaging reported its second quarter 2024 results, with a revenue of US$2.70m, up 4.5% from the same period in 2023. However, the companys net loss stood at US$13.6m, although this was a 22% improvement from 2Q 2023. The companys earnings per share also improved, with a loss of US$0.23 compared to a loss of US$0.31 in 2Q 2023. Despite these improvements, the companys revenue and earnings per share missed analyst estimates by 31% and 6.2% respectively. Looking ahead, the companys revenue is forecast to grow 48% per annum on average over the next three years.
Customers
growth-positive
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery Calcium
Nano-X Imaging LTD announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for HealthCCSng V2.0. This is an upgraded version of Nanox.AI’s cardiac solution, HealthCCSng, which has shown tangible results in several healthcare systems, identifying patients at high risk of coronary artery disease. The product uses medical imaging data from routine non-gated, non-contrast CT scans to automatically measure coronary artery calcium (CAC), a key risk predictor for future cardiovascular events.
CustomersPartners
growth-positive
Q2 2024 Nano-X Imaging Ltd Earnings Call
Nano-X Imaging Ltd has released its financial results for Q2 2024, showing strong commercial progress and advancements in product value through clinical efforts. The company is accelerating the deployment of its Nanox.ARC system and expanding the footprint of its Nanox.AI solution. Nano-X has submitted a new 510(k) submission to the FDA to expand the indications for the Nanox.ARC system in general tomosynthesis imaging. The company is also in advanced stages with its Notified Body to secure the CE mark for the EU region. The company has installed the Nanox.ARC system in three prominent healthcare chains in the US and is awaiting import license to deploy the first Nanox.ARC in Mexico. The company is also developing another Nanox system called Nanox.ARC X.
CustomersInvestmentManagement ChangesExpand
growth-positive
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update
Nano-X Imaging LTD has announced its Q2 2024 results, revealing a revenue of $2.7 million, up from $2.6 million in Q2 2023. The company has also submitted a new 510k application to the FDA to expand the use cases for its Nanox.ARC technology. The company has installed its systems in seven US states and has a robust sales pipeline. It has also developed a system called Nanox.ARC X, which will be introduced at the next investor relations event. The companys AI Cardiac Solution, HealthCCSng, was highlighted at the 2024 SSCCT annual meeting.
CustomersInvestmentManagement ChangesExpand
growth-positive
Nano-X Imaging (NNOX) Q2 2024 Earnings Call Transcript
Nano-X Imaging held its Q2 2024 earnings call, during which it reported a GAAP net loss of $13.6 million, compared to a net loss of $17.4 million in Q2 2023. The company also announced that it has submitted a new 510k submission to the FDA to expand the indications for its current Nanox.ARC System in general tomosynthesis imaging. The company is also developing another Nanox.ARC system, called Nanox.ARC X, which it plans to submit for FDA clearance. The company is also expanding its commercial efforts and has installed its Nanox.ARC system in three prominent healthcare chains in the US.
CustomersPartnersManagement ChangesExpand
Growth-Negative
These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter
Nvidias 13F filing revealed that the company held stakes in Arm, SoundHound AI, Nano X Imaging, Recursion Pharmaceuticals, and Serve Robotics at the end of Q2. Most of these stocks lost ground during the quarter, but have still gained since the start of the year. Arm, SoundHoundAI, and Serve have outperformed the S&P 500 this year, while Nano X Imaging and Recursion Pharmaceuticals have underperformed. Nvidias stake in Arm is its most valuable, worth over $320 million at the end of June.
Investment
Growth-Positive
3 Artificial Intelligence (AI) Stocks That Could Go Parabolic
The article discusses the potential of three companies, Nano-X Imaging, Riskified, and Rubrik, that are leveraging AI in their operations. Nano-X Imaging is developing an innovative X-ray imaging device, with AI solutions for interpreting patients scans. Riskified, an AI fraud and risk intelligence company, helps e-commerce companies reduce operating expenses and improve customer experiences. Rubrik, a cybersecurity specialist, offers a comprehensive solution for organizations looking to protect their data, with the assistance of AI and machine learning. All three companies are seen as having significant growth potential.
InvestmentCustomers
Neutral
Nanox to Report Second Quarter and Financial Results on August 20, 2024
Nano-X Imaging LTD, an innovative medical imaging technology company, will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. CEO Erez Meltzer and CFO Ran Daniel will host a conference call to review these results and provide a business update. The companys vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives.
Management Changes
growth-positive
Ledger launches Ledger Flex, a mid-range hardware crypto wallet
French startup Ledger has launched a new mid-range crypto hardware wallet, the Ledger Flex, priced at $249. The device features an E-Ink display for navigating the interface and approving transactions. The private keys of the wallet are stored in a secure element, ensuring the safety of crypto assets even if the users computer or phone is compromised. The Ledger Flex is designed as a cheaper version of the Ledger Stax, which was developed in partnership with Tony Fadell and costs $399.
CustomersPartners
growth-positive
Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024
Nano-X Imaging LTD announced that its subsidiary, Nanox.AI Ltd.s AI Cardiac Solution, was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. The AI solution was used in studies conducted by Brigham & Women’s Hospital, Jefferson Einstein Hospital, Corewell Health, Massachusetts General Hospital, and Rabin Medical Center. The studies demonstrated the potential of the AI solution in early detection and preventive care of cardiovascular disease, and its positive impact on hospital revenue. The solution was also shown to be useful in identifying patients with undiagnosed Coronary Artery Disease.
CustomersPartners
growth-positive
Nanox Highlights AI Cardiac Solution at SCCT 2024
Nanox Imaging Ltd. showcased its AI Cardiac Solution (HealthCCSng) at SCCT 2024. The solution was used in various studies by Corewell Health, Jefferson Einstein Hospital, Massachusetts General and Brigham & Women’s Hospitals, and Rabin Medical Center. The studies showed that HealthCCSng was able to identify new patients with significant Coronary Artery Calcium (CAC), suggesting AI’s potential in identifying at-risk patients and enabling preventive cardiology interventions. Nanoxs CEO, Erez Meltzer, expressed his encouragement by the implementation of their AI cardiac solution at esteemed healthcare systems.
Customers
growth-positive
Is MoneyLion (ML) Stock Outpacing Its Business Services Peers This Year?
MoneyLion Inc. is outperforming its peers in the Business Services sector, according to Zacks Investment Research. The companys stock has returned about 13.6% since the start of the year, compared to the sectors average return of 10.9%. The Zacks Consensus Estimate for MoneyLions full-year earnings has moved 2516.7% higher over the past 90 days, indicating strong analyst sentiment and an improving earnings outlook. MoneyLion is currently sporting a Zacks Rank of #2 (Buy).
Investment
growth-positive
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street
Nvidia has invested in several potential rising stars of the AI world, including Nano-X Imaging, Recursion Pharmaceuticals, and Soundhound AI. Wall Street analysts predict these Nvidia-backed stocks could soar 73% to 89% higher. Nano-X Imaging, a small medical technology company, develops cost-effective medical imaging technology and uses AI to diagnose undetected chronic diseases. Recursion Pharmaceuticals, a TechBio company, uses technology for drug discovery and development. Soundhound AI, a leader in developing voice AI systems, has seen its share price almost double in 2024.
InvestmentPartners
growth-positive
Nvidia Is Buying Shares of These 5 AI Companies. Should You Do the Same?
Nvidia, a dominant producer of high-end data center GPUs, has been investing in smaller AI companies. The company disclosed its investments in SoundHound AI, Arm Holdings, Recursion Pharmaceuticals, Nano-X Imaging, and TuSimple Holdings. SoundHound AI and Arm generated much bigger gains than the other three stocks. SoundHound develops audio and speech recognition technologies, and Arm designs power-efficient chips used in premium smartphones. Recursion uses AI algorithms for drug discovery tests, Nano-X produces digital X-ray sources and develops AI tools for identifying undetected chronic diseases, and TuSimple is a Chinese autonomous trucking company.
Investment
growth-positive
Is NanoX Imaging (NNOX) Outperforming Other Business Services Stocks This Year?
Nano-X Imaging Ltd. is outperforming its peers in the Business Services sector, according to Zacks Investment Research. The companys full-year earnings estimate has increased by 5% in the past quarter, indicating an improving sentiment among analysts. So far this year, Nano-X Imagings stock has returned 7.4%, slightly above the sectors average return of 7.3%. However, the company is slightly underperforming in the Technology Services industry, which has gained an average of 23.3% this year.
None
growth-positive
Data Supporting Nanox.AI Cardiac Solution to Be Presented at 19th Annual Meeting of the Society of Cardiovascular Computed Tomography
Nano-X Imaging LTD, a medical imaging technology company, has announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT). The studies are being presented by Brigham & Women’s Hospital, Einstein Jefferson Medical Center, Corewell Health, Massachusetts General Hospital and Beilinson Medical Center. The AI Cardiac Solution utilizes medical imaging data from routine chest CT scans to automatically quantify coronary artery calcium (CAC) levels, a strong predictor of future cardiovascular events.
CustomersPartners
growth-positive
7 Futuristic Tech Stocks to Tap Into ASAP
The article discusses seven tech stocks that investors should consider for their portfolios. These include NXP Semiconductors, a Netherlands-based company that designs and manufactures high-performance mixed-signal semiconductors; Garmin, a multinational tech giant specializing in consumer-oriented products; Ambarella, a fabless semiconductor design company; Arista Networks, a company that focuses on network computing; Innoviz Technologies, an Israeli company that specializes in automotive-grade lidar sensors and perception software; Coursera, a global massive open online course provider; and Nano-X Imaging, an Israeli company that develops digital X-ray solutions based on semiconductor technology.
Investment
growth-positive
Are Business Services Stocks Lagging NanoX Imaging (NNOX) This Year?
Nano-X Imaging Ltd. is outperforming the Business Services sector with a year-to-date return of 13.5%, compared to the sectors average return of 6.7%. The companys full-year earnings consensus estimate has increased by 18.5% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook. The company currently has a Zacks Rank of #2 (Buy). Another Business Services stock, Seagate, has also outperformed the sector with a year-to-date return of 24.2%.
Investment
growth-positive
Down -19.76% in 4 Weeks, Here's Why NanoX Imaging (NNOX) Looks Ripe for a Turnaround
Nano-X Imaging Ltd. (NNOX) has seen a significant decline in its stock, with a 19.8% drop over the past four weeks. However, the stock is now in oversold territory, and Wall Street analysts predict that the company will report better earnings than previously expected. The companys Relative Strength Index (RSI) reading is 29.02, indicating that the heavy selling of NNOX shares may be nearing its end. Additionally, there has been a strong consensus among analysts to raise earnings estimates for the current year. NNOX currently has a Zacks Rank #2 (Buy), indicating a potential turnaround in the near term.
growth-positive
Nanox Integrates AI for Enhanced Second Opinion CT Scan Reviews
NANO-X IMAGING LTD has integrated FDA-cleared AI solutions into its Second Opinions online consultation service, offered by its subsidiary, USARAD Holdings INC. The platform connects patients with specialists for additional diagnostic consultations. The AI tools are used for early detection of chronic conditions through CT scans, including early signs of coronary artery disease, osteoporosis risks, and fatty liver disease.
CustomersPartners
growth-positive
Bears are Losing Control Over NanoX Imaging (NNOX), Here's Why It's a 'Buy' Now
Shares of Nano-X Imaging Ltd. have been struggling recently, losing 6.8% over the past week. However, a hammer chart pattern was formed in its last trading session, which could indicate a trend reversal. This pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. Additionally, there has been an upward trend in earnings estimate revisions for the company, which can be considered a bullish indicator. The company currently has a Zacks Rank #2 (Buy), indicating it is in the top 20% of more than the 4,000 stocks that Zacks ranks based on trends in earnings estimate revisions and EPS surprises.
Growth-Positive
Nvidia Owns These 4 Stocks. Here’s How They’re Doing.
The article discusses the strong performance of Nvidia on Wall Street since 2023. It mentions that Nvidia has amassed holdings in four companies during this period, but does not provide further details about these investments.
growth-positive
Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform
Nano-X Imaging LTD has integrated FDA-cleared population health AI solutions into its Second Opinions service. The AI functionality is provided by Nanox AI Ltd., a subsidiary of Nano-X Imaging Ltd. The AI tools are designed to promote early detection of chronic conditions on chest and abdominal CT scans. The AI-driven insights are reviewed and approved by Second Opinions physicians and incorporated into reports for patients who submit eligible chest and abdominal CT scans. The integration of these AI solutions will help empower radiologists and other healthcare providers by providing them with advanced AI tools that aim to improve patient outcomes.
CustomersPartners
growth-positive
Is NanoX Imaging (NNOX) Stock Outpacing Its Business Services Peers This Year?
Nano-X Imaging Ltd. (NNOX) is outperforming its peers in the Business Services sector, with a year-to-date gain of 27.3%, compared to the sectors average gain of 3.7%. The companys full-year earnings outlook has improved, with the Zacks Consensus Estimate moving 15.2% higher in the past quarter. The company currently holds a Zacks Rank of #2 (Buy). Nano-X Imaging Ltd. belongs to the Technology Services industry, which has gained about 13.8% so far this year. The company is also outperforming this group.
growth-negative
Down 53%. Is Nano-X Imaging a Buy on the Dip?
Nano-X Imagings stock has seen a significant decrease over the past year, despite earning FDA clearance for its Nanox.ARC device. The device, which uses less electricity to produce X-rays, has not seen the sales growth investors had hoped for. Additionally, the companys AI solution, Nanox.AI, has not been profitable. Nvidia, one of Nano-Xs investors, holds 59,632 shares of the company. However, the article suggests that this should not be seen as a direct endorsement of Nano-Xs AI ambitions. The company ended March with $44.9 million in cash after losing over $12 million in Q1.
Investment
growth-positive
Nanox Announces First Quarter of 2024 Financial Results and Provides Business Update
Nano-X Imaging LTD announced its Q1 2024 results, reporting $2.6 million in revenue, up from $2.4 million in Q1 2023. The company also announced it has secured agreements for its Nanox.AI with Dandelion Health and Covera Health. Additionally, Nano-X has entered into an agreement with US-based Swissray, a provider of radiology services, to strengthen its customer support infrastructure. The company also hosted a live demonstration of the Nanox.ARC, scanning a patient at Dynamic Medical Imaging in New Jersey. The company reported a net loss of $12.2 million for Q1 2024, compared to a net loss of $11.8 million for Q1 2023.
CustomersPartners
growth-positive
Ledger starts shipping its high-end hardware crypto wallet
French startup Ledger, known for its secure crypto hardware wallets, has started shipping its new Ledger Stax devices. The updated wallet, designed in partnership with iPod designer Tony Fadell, features an E Ink display and is aimed at high-end customers. The Ledger Stax, which was delayed due to production difficulties with the curved E Ink display, also marks the beginning of a production partnership with Foxconn. Ledger has sold over 6 million devices to date and estimates it secures around 20% of the worlds crypto assets.
CustomersPartners
growth-positive
1 Supercharged Growth Stock Poised to Trounce the S&P 500
Medical imaging specialist Nanox is identified as a top market-beating candidate in the stock market over the current decade. The companys innovative approach to medical imaging, including its multi-source digital tomosynthesis system Nanox.ARC and its Nanox.AI platform, is expected to transform the field of medical imaging. Despite being expected to remain cash-flow-negative in the short term, profitability is a real possibility by 2026. The companys market cap is currently $503 million, and it is suggested that the stock has a decent shot at going on a multi-year bull run.
Investment
Growth-Positive
Nanox to Report First Quarter and Financial Results on May 28, 2024
Nano-X Imaging LTD, an innovative medical imaging technology company, announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. CEO Erez Meltzer and CFO Ran Daniel will host a conference call to review these results and provide a business update. The company is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Its ecosystem includes a multi-source Digital Tomosynthesis system, an AI-based suite of algorithms, a cloud-based infrastructure, and a proprietary decentralized marketplace.
Management Changes
growth-positive
USARAD, Nanox’s Teleradiology Subsidiary, Awarded Accreditation from The Joint Commission
Nano-X Imaging LTD, a medical imaging technology company, has announced that its subsidiary, USARAD Holdings, Inc., has earned The Joint Commission’s Gold Seal of Approval for Ambulatory Health Care Accreditation for the sixth time. This accreditation is a symbol of quality that reflects a health care organization’s commitment to providing safe and quality patient care. USARAD is a U.S.-based teleradiology company with a network of approximately 60 radiologists, certified by the American Board of Radiology.
CustomersPartners
growth-positive
Nanox to Participate in Three Upcoming Investor Conferences in May 2024
Nano-X Imaging LTD, an innovative medical imaging technology company, announced that its management will participate in three investor conferences in May 2024. These include the EF Hutton 2024 Annual Global Conference, the AGP 2024 Healthcare Conference, and the Benchmark 2024 Healthcare House Call Virtual Conference. The companys CEO, Erez Meltzer, and CFO, Ran Daniel, will engage in 1x1 investor meetings and deliver presentations. The company aims to make diagnostic medicine more accessible and affordable globally through its proprietary medical imaging technology and solutions.
Investment
Growth-Negative
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
The article discusses the risks of investing in biotech stocks, particularly Ironwood Pharmaceuticals, Nano-X Imaging, and Cassava Sciences. Ironwood Pharmaceuticals has seen a decrease in value due to lackluster trial results and competition. Nano-X Imaging, despite its innovative approach to X-ray technology, lacks tangible results and has seen a drop in cash and short-term investments. Cassava Sciences, known for its Alzheimers treatment, has faced controversies surrounding its trials, leading to skepticism and increased net losses. The author advises investors to avoid these stocks due to the current state of the stock market.
InvestmentManagement Changes
Neutral
Nanox Files 2023 Annual Report on Form 20-F
Nano-X Imaging LTD, an innovative medical imaging technology company, has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission on April 22, 2024. The report contains the companys audited consolidated financial statements. The company is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The Nanox ecosystem includes various products and services that connect medical imaging solutions, from scan to diagnosis.
Public Trading
growth-positive
ChatGPT Stock Predictions: 10 Stocks That Have 10X Potential
ChatGPT, an AI chatbot, has been used to predict stocks with the potential to grow 10X in the next few years. The AI has been used by hedge funds, venture capitalists and investors to spot potential multibaggers. The AI software developed by Sierra Ventures has been used to decide whether to invest in a startup. The AI has been used in the investing world for sentiment analysis, finding patterns in stocks and predicting market movements. Some of the top stocks predicted by ChatGPT include Alphabet Inc, Nvidia Corp and Palantir Technologies Inc.
CustomersInvestment
growth-positive
Q2 AI Watch: 3 Stocks to Keep Your Eyes On Now
The article discusses the potential growth of three companies, ASML Holdings, Nano-X Imaging, and Micron Technology, due to their integration of AI technology. ASML Holdings, a leading manufacturer of chipmaking technology, is expected to benefit from the increasing demand for AI infrastructure. Nano-X Imaging, a healthcare company, uses AI to improve disease detection and diagnosis. Micron Technology, a computer memory storage company, is addressing the AI industrys need for memory storage. The article suggests that these companies stocks are worth watching due to their potential return on investment.
Investment
Growth-Positive
Nano-X Imaging Ltd. (NASDAQ:NNOX): Are Analysts Optimistic?
Nano-X Imaging Ltd., a company that develops commercial-grade tomographic imaging devices, is expected to reach breakeven in about two years, according to industry analysts. The company, which posted a loss of $61m for its most recent financial year, is predicted to post a final loss in 2025, before turning a profit of $104m in 2026. This forecast is based on an average annual growth rate of 69%. The company has managed its capital judiciously, with debt making up only 1.8% of equity.
Investment
growth-positive
Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market
Nano-X Imaging LTD has announced a new collaboration with AhealthZ and SCL Science to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in South Korea. AhealthZ will assist Nanox in securing local authorizations and licenses for the importation, marketing, and sales of the Nanox.ARC in South Korea. SCL Science will integrate Nanox’s AI solutions in remote image analysis and other operations. The collaboration aims to bring comprehensive medical imaging solutions to South Korea and expand Nanoxs AI solutions portfolio.
PartnersExpand
growth-positive
Nano-X Imaging Ltd. (NASDAQ:NNOX) Q4 2023 Earnings Call Transcript
Nano-X Imaging Ltd. reported its Q4 2023 earnings, highlighting significant progress in its operations. The company has received FDA clearance for its Nanox.ARC system and has begun commercialization in the U.S. The company has also expanded its operations to Africa and Latin America. The companys AI business has seen a 250% increase in its client base compared to the previous quarter. The company also reported a GAAP net loss for Q4 2023 of $10.2 million, a significant decrease from the net loss of $52.8 million in Q4 2022. Revenue for Q4 2023 was $2.4 million.
CustomersPartnersExpand
growth-positive
Nano-X Imaging (NNOX) Q4 2023 Earnings Call Transcript
Nano-X Imaging Ltd. reported its Q4 2023 earnings call, highlighting significant progress in the companys operations. The company has received FDA clearance for its Nanox.ARC system and has begun commercialization in the U.S. The system has been deployed in several medical imaging and diagnostic system centers across five states. The company has also expanded its footprint in Africa and Latin America, generating revenue from hardware deployments. Furthermore, Nano-Xs AI business has seen a 250% increase in its client base compared to the previous quarter. The companys financial results show a decrease in net loss from $52.8 million in Q4 2022 to $10.2 million in Q4 2023.
CustomersExpand
growth-positive
ננוקס מאיצה את פריסת מערכות הרנטגן בארה"ב - Techtime - חדשות אלקטרוניקה והייטק
Nanox, an Israeli medical imaging company, has expanded its operations in the United States, installing its systems in five states and beginning to generate revenue from patient scans. The company received FDA approval a year ago and made its first commercial installation in a New Jersey medical center. Nanox has also installed three systems in Africa, signed a distribution agreement in Peru, and sent two systems to Mexico pending local regulatory approval. The company reported a 250% growth in its customer base for its AI solutions, based on technology from Zebra Medical, which it acquired. In the fourth quarter of 2023, the company recorded revenues of $2.1 million and a net loss of $10.2 million.
ExpandCustomers
growth-positive
Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update
Nano-X Imaging LTD has announced the launch of Nanox.ARC in the United States, with installations across five states. The company generated $2.4 million in revenue in the fourth quarter of 2023, compared to $2.1 million in the fourth quarter of 2022. The Nanox.ARC systems have been deployed in five states and have begun scanning patients. The companys Nanox.AI secured FDA clearance for HealthFLD, an advanced AI-based software for the assessment of fatty liver disease. InterMountain Health has signed on to deploy HealthCCS. The company also reported a net loss of $10.2 million for the fourth quarter of 2023.
CustomersPartnersManagement Changes
Is Nano-X Imaging Stock a Buy in the New Bull Market?
Growth-Positive
Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
Nano-X Imaging LTD, an innovative medical imaging technology company, has announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, on April 1, 2024. The companys CEO, Erez Meltzer, and CFO, Ran Daniel, will host a conference call to review these results and provide a business update. The company is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe.
Management Changes
growth-positive
Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold
Nano-X Imaging LTD and its subsidiary, Nanox.AI, have announced that their AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study has identified up to six times more patients with vertebral compression fracture than the national average at National Health Services (NHS) hospitals in the UK. The study uses Nanox.AIs artificial intelligence solution, HealthVCF, to review routine CT scans. The study has so far identified over 2,400 patients with VCF from routine CT scans that were not known to the NHS’s hospitals, and have since been flagged for follow-up assessments. The study will continue through February 2025.
CustomersPartners
growth-positive
Here's Why Nano-X Stock More Than Doubled Last Month
Shares of medical imaging start-up Nano-X Imaging rose by 105.1% in February after a regulatory filing revealed that Nvidia had a stake in the company. However, the stake was acquired indirectly through Nvidias investment in Zebra Medical in 2017, which was later acquired by Nano-X in a stock deal worth almost $200 million. Despite the markets positive reaction, the author suggests that Nvidias stake in Nano-X is inconsequential. Nano-X, which is trying to disrupt the X-ray industry with its digital-imaging technology, recently received FDA clearance for its AI software to assess images of fatty livers.
InvestmentAcquisition
growth-positive
Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases
Nano-X Imaging LTD, an innovative medical imaging technology company, has announced a collaboration with Beilinson Hospital, a leading Israeli hospital, to conduct a clinical study evaluating the Nanox.ARC 3D imaging system. The study will assess the diagnostic capabilities of the Nanox.ARC’s tomographic imaging system compared with conventional two-dimensional radiography for detection of lung and chest disease in adults. This collaboration aims to provide further clinical validation of the Nanox.ARC and develop a globally connected medical imaging solution.
PartnersExpand
growth-positive
Nano-X Imaging Could Be Teaming Up With Nvidia, and Its Stock Is Flying. Can It Continue?
Nvidia has acquired a stake in Nano-X Imaging, an Israeli medical device company that manufactures X-ray machines. The investment, though small, led to a significant increase in Nano-Xs shares. Nano-Xs unique business model involves distributing its low-cost X-ray machines and generating revenue each time a customer performs a scan. The company is also developing AI systems to remotely analyze the images generated by its hardware, which could be a reason for Nvidias interest. In 2017, Nvidia invested in Zebra Medical, another Israeli company focused on AI for interpreting scan imagery. Nano-X later acquired Zebra Medical.
InvestmentPartners
growth-negative
Cathie Wood Was Buying These 11 Stocks for 2024
The article discusses the investment decisions of Cathie Wood, the founder of ARK Investment Management. It highlights that despite the loss of about $14.3 billion in shareholder value over the past decade, ARK ETF Trust has not seen a mass investor exodus. The article suggests that this could be due to Woods investment philosophy, which requires a minimum five-year investment horizon. It also mentions that Woods decision to sell Nvidia in January 2023 has been questioned by investors. The article lists 11 stocks that Wood was buying for 2024, including Nano-X Imaging Ltd., Pagaya Technologies Ltd, Inmode Ltd, Pure Storage Inc., SoFi Technologies Inc., and Nextdoor Holdings Inc.
InvestmentManagement Changes
growth-positive
These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours?
Nvidia has disclosed its investments in healthcare companies Nano-X Imaging and Recursion Pharmaceuticals. Nano-X Imaging, which makes X-ray beds that simplify the imaging process, is still in the early stages of commercializing its product and has a long road ahead. Recursion Pharmaceuticals, Nvidias largest stake after Arm Holdings, is working with Nvidia on accelerating drug discovery using AI and Nvidias cloud service BioNeMo. However, Recursions business is also unproven, with programs no further along than phase 2 trials.
Investment
growth-positive
Stocks owned by Nvidia saw surge in bullish bets days before filing sparked massive rally
Trading in bullish options contracts tied to two small-capitalization companies owned by chipmaker Nvidia Corp. surged last week just days before the company released a routine filing. The filing of Nvidia’s first 13-F filing with the U.S. Securities and Exchange Commission last Wednesday triggered a rally in their shares, leaving the buyers of these call options sitting on huge gains on the day the contracts were set to expire. Options volume for bullish call options tied to Nano-X Imaging, a small Israeli medical-device company, and SoundHound saw a similar spike in demand. Nvidia has owned small amounts of New York-listed Nano-X and SoundHound stock for several years.
InvestmentPublic Trading
Growth-Positive
Nvidia Is Investing in These 3 Stocks. Should You?
Nvidia has invested in several artificial intelligence (AI) stocks, including SoundHound AI, Nano-X Imaging, and Arm Holdings. SoundHound AI offers AI voice solutions to businesses, but its financials and valuation make it a risky investment. Nano-X Imaging, a medical imaging technology company, also appears overvalued despite Nvidias investment. Arm Holdings, a semiconductor company, has a high valuation but stands to benefit from increased demand for AI chips. However, Nvidias investment in these companies does not necessarily indicate their success, as fundamentals are crucial.
Investment
growth-positive
Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.
Nvidia has announced its investment in five artificial intelligence (AI) stocks, including Arm Holdings, Nano-X Imaging, Recursion Pharmaceuticals, Soundhound AI, and TuSimple Holdings. The largest investment was in Arm Holdings, with Nvidia purchasing around 1.96 million shares worth over $250 million. Other investments include over 7.7 million shares in Recursion Pharmaceuticals, nearly 3.47 million shares in TuSimple Holdings, and smaller stakes in Nano-X Imaging and Soundhound AI. The investments come as Nvidia is expected to report full-year revenue of around $60 billion.
Investment
Growth-Positive
Nvidia’s Nano-X Stake Is From Biotech Deal, Not Direct Buy
Shares of several companies, including Nano-X Imaging Ltd., have rallied after Nvidia Corp. disclosed owning stakes in them. Nvidias stake in Nano-X came about when the chipmaker reported a stake in Zebra Medical in 2017, which was later acquired by Nano-X in an all-stock deal. This resulted in Nvidia receiving shares in Nano-X in return for its Zebra stake. However, Nvidia did not consciously choose to buy Nano-X stock. The chipmaker made the disclosures in a 13-F regulatory filing, required for institutional investors whose portfolios exceed $100 million.
Investment
Growth-Positive
Trending tickers: Nvidia, Nike, Coinbase, Eni
Nvidias stock has seen a rise after the company disclosed investments in several emerging AI companies, including Soundhound, Arm, and Nanox. This has led to rallies across those involved in the deal. Nvidias shares have increased nearly 50% since the start of 2024 and more than 220% in the past year. The companys market cap has recently surpassed that of Amazon and Alphabet, with only Microsoft and Apple having a higher valuation. Meanwhile, Nike announced a workforce cut of around 2%, or 1,600 jobs, to offset costs after weaker profits this year.
Investment
growth-positive
Nvidia Discloses Stakes In Arm, SoundHound AI, Nano-X And More
Nvidia has disclosed investments in several companies including Arm Holdings, SoundHound AI, and Nano-X Imaging. The AI chip giant also announced small stakes in Recursion Pharmaceuticals and self-driving company TuSimple Holdings. Nvidias stock edged lower early Thursday while the stocks of the companies it invested in saw significant increases. Nvidia had previously attempted to buy Arm Holdings for $40 billion in 2020 but gave up in 2022 due to regulatory objections.
Investment
Shares of SoundHound, Nano-X Surge on News that Nvidia Owns Stakes
growth-positive
Nvidia bets on AI future with new investments, shares rally
Nvidia has disclosed its investments in several emerging AI companies, including Soundhound, Arm, and Nanox. This has led to a boost in the stocks of these companies. The largest investment was in Arm, at about $147 million. Nvidia had previously attempted to acquire Arm, but this did not go through due to regulatory challenges. Other investments include $76 million in Recursion Pharmaceuticals and $4 million in SoundHound. The news has sparked enthusiasm in the market, leading to gains in the stocks of these companies.
Investment
growth-positive
Smaller AI firms surge after chip giant Nvidia discloses stake
Nvidia has disclosed stakes in four smaller AI firms, causing their shares to surge. The chipmaker revealed its new stakes in a 13-F filing with the US Securities and Exchange Commission. Nvidia took a stake worth nearly $3.7 million in SoundHound AI, a developer of conversational voice assistants, causing shares in the firm to rise by more than 50%. Its largest investment of $147.3 million was in Arm Holdings. Nvidia also invested nearly $76 million in biotech firm Recursion Pharmaceuticals and bought shares of Israel-based medical device company Nano-X Imaging. Autonomous driving technology TuSimple Holdings also received $3 million in capital from Nvidia.
Investment
growth-positive
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Nano-X Imaging LTDs subsidiary, Nanox AI Ltd., has received FDA clearance for HealthFLD, an AI software that provides automated analysis of liver attenuation from routine CT scans. The software is intended to support clinicians in the detection of fatty liver, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD). The software is the third product in Nanox AIs suite of population health solutions to become commercially available. The clearance expands Nanoxs offering in AI solutions and could potentially improve health outcomes by aiding in the early detection of liver diseases.
CustomersExpand
growth-negative
Nanox Mourns Death of Its Founder, Ran Poliakine
Nano-X Imaging LTD announced the death of its founder and non-executive chairman, Ran Poliakine. Poliakine, who passed away due to a medical condition, was instrumental in the early development of the companys proprietary medical imaging technology and solutions. After founding Nanox and leading the company to go public in 2020, he moved to a non-executive role in 2021. The companys board of directors will be meeting in the coming days to initiate the process of appointing a new board chair.
Management Changes
growth-positive
משרד הבריאות אישר את הרנטגן של ננוקס - Techtime - חדשות אלקטרוניקה והייטק
The Israeli Ministry of Health has approved the use of Nanoxs X-ray device, Nanox.ARC, in hospitals and imaging institutes for CT scans. This approval allows the company to market its device to medical institutions in Israel. Nanox has also signed an agreement with Clalit Health Services to conduct clinical research at Ichilov Hospital. The company has installed its first commercial system in New Jersey and has begun generating initial revenues from its systems in Africa. Nanox has also received regulatory approval in Ghana, where it has already installed a system at the Medical University of Ghana and received additional orders.
CustomersPartnersExpand
growth-negative
Nano-X Imaging Ltd. (NASDAQ:NNOX) Q3 2023 Earnings Call Transcript
Nano-X Imaging Ltd. reported its Q3 2023 earnings, missing expectations with a reported EPS of $-0.37, compared to the expected $-0.3. The company announced its expansion into the US market, with the establishment of a commercial site and demonstration center in New Jersey. It also signed an agreement with 626, a healthcare technology and equipment management company, to provide services for the Nanox.ARC. Additionally, the company has begun to generate revenues from hardware deployment in Africa and has installed a unit in the University of Ghana Medical Center Ltd. The company also announced regulatory progress, receiving approval from the Israeli Ministry of Health for the Nanox.ARC.
Management ChangesExpand
growth-positive
Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update
Nano-X Imaging LTD has reported progress towards global supply chain development and commercial deployment. The company ended Q3 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million. Nano-X entered into a manufacture and supply agreement with Varex Imaging Corporation, under which Varex will supply X-ray tubes for the Nanox.ARC system. The company also generated $2.5 million in revenue in Q3 2023, compared to $2.4 million in Q3 2022. Nano-X has also received regulatory approval from the Ghana Food and Drugs Authority for the Nanox.ARC system deployed at the University of Ghana Medical Centre.
PartnersCustomersExpand
Nano-X Imaging (NNOX) Q3 2023 Earnings Call Transcript
Growth-Positive
Nanox to Report Third Quarter 2023 Financial Results on November 28, 2023 and Reschedules Investor Day for December 4, 2023
Nano-X Imaging LTD, an innovative medical imaging technology company, has announced that it will report its financial results for the quarter ended September 30, 2023, on November 28, 2023. The company will also hold its Investor Day on December 4, 2023, at the Nasdaq building in New York City. The companys vision is to make diagnostic medicine more accessible and affordable across the globe. Its ecosystem includes a multi-source Digital Tomosynthesis system, an AI-based suite of algorithms, a cloud-based infrastructure, and a proprietary decentralized marketplace that provides remote access to radiology and cardiology experts.
Investment
growth-positive
Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Path To Profitability
Nano-X Imaging Ltd., a company that develops commercial-grade tomographic imaging devices, is expected to reach breakeven in 2025 according to analysts. The companys loss has lessened from US$113m to US$101m as it approaches breakeven. Analysts expect the company to grow 65% year-on-year, on average, to reach the breakeven point by 2025. The company has managed its capital judiciously, with debt making up 1.8% of equity.
Investment
Neutral
Nanox Continues Business as Planned, and Postpones Investor Day Scheduled for October 17, 2023
Nano-X Imaging LTD has announced the postponement of its Investor Day, originally scheduled for October 17, 2023, due to recent events in Israel. The companys CEO, Erez Meltzer, stated that the decision was made as an act of solidarity. Despite this, the companys US operations and go-to-market strategy will continue as planned. The new date for the Investor Day will be announced in the coming weeks.
Management Changes
growth-positive
Nanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging System
Nano-X Imaging LTD has entered into a manufacturing and supply agreement with Varex Imaging Corporation. Under the agreement, Varex will supply X-ray tubes for the Nanox.ARC system. The partnership comes after Varex completed an assessment of Nanoxs digital X-ray source. The Nanox.ARC system uses a proprietary digital cathode X-ray source that Nanox believes can achieve the same functionalities as legacy X-ray cathodes, but at a lower cost. The company also plans to add AI technology to its imaging solution in the future. The agreement allows Nanox to order X-ray tubes from Varex for its Nanox.ARC system, with Varex manufacturing and supplying the tubes in exchange for a revenue-sharing fee.
Partners
growth-positive
Nanox to Host Investor Day on October 17, 2023
Nano-X Imaging LTD, a medical imaging technology company, has announced that it will host an Investor Day at the Nasdaq in New York City on October 17, 2023. The event will include presentations and Q&A sessions with leaders from across the company. The companys vision is to make diagnostic medicine more accessible and affordable globally, with a focus on early detection and treatment. The Nanox ecosystem includes a multi-source Digital Tomosynthesis system, an AI-based suite of algorithms, a cloud-based infrastructure, and a proprietary decentralized marketplace.
Investment
growth-positive
Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs
Nano-X Imaging LTD announced that its AI-powered solution, HealthCCSng, was used in a clinical study to assess coronary artery calcium (CAC) measurements. The study found that 58% of patients unknowingly had moderate to severe levels of CAC, a proven indicator of future cardiac events. The study was conducted by Beilinson Hospital in Israel and sponsored by Nanox.AI. HealthCCSng utilizes medical imaging data from routine chest CT scans to automatically quantify and analyze CAC category. The results of the study highlight the potential of AI in early risk identification and prevention of cardiac events.
CustomersPartners
growth-positive
Nanox to Present at the Cantor Fitzgerald Global Healthcare Conference 2023 in September
Nano-X Imaging LTD, an innovative medical imaging technology company, has announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2023. The conference will be held on September 26-28, 2023 at the InterContinental Barclay Hotel in New York City. The companys CEO, Erez Meltzer, and CFO, Ran Daniel, will engage in a fireside chat and host investor 1x1 meetings. The companys vision is to make diagnostic medicine more accessible and affordable across the globe.
Investment
growth-negative
3 Magnificent Growth Stocks to Buy on the Dip
Growth stocks in the fields of drug development and medical imaging, including Agenus, BioCryst Pharmaceuticals, and Nano-X Imaging, have experienced a significant drop in their stock prices in the past 30 days.
Public Trading
growth-negative
Nano-X Imaging Second Quarter 2023 Earnings: Misses Expectations
Nano-X Imaging reported a net loss of US$17.4m in the second quarter of 2023, narrowing the loss by 12% compared to the same period in 2022. However, the companys revenue and earnings missed analyst estimates by 17%. Looking ahead, Nano-X Imaging is forecasted to have an average annual revenue growth of 75% over the next 3 years, outperforming the 7.9% growth forecast for the Medical Equipment industry in the US. The companys shares have declined by 13% in the past week. Nano-X Imaging has 2 warning signs that investors should be aware of. This article provides general information and analysis based on historical data and analyst forecasts.
CustomersInvestment
ננוקס גיבשה אסטרטגיה לחדירה לשוק האמריקאי - Techtime - חדשות אלקטרוניקה והייטק
Nano-X Imaging Ltd. (NASDAQ:NNOX) Q2 2023 Earnings Call Transcript
growth-positive
Nano-X Imaging (NNOX) Q2 2023 Earnings Call Transcript
Nano-X Imaging released its financial results for Q2 2023. The company had a growth-positive impact. The key theme of the article is the earnings call. The structured issue discussed is investment. The article discusses topics such as Q2 2023 earnings, financial results, the CEO, the CFO, and the call transcript. No specific investors or acquisition amounts are mentioned. The event described in the article occurred on an unspecified date. Confidence level: 8
Investment
growth-positive
Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update
Nano-X Imaging LTD has reported a successful Q2 2023, with progress in global supply chain development and $80.3 million in cash and equivalents. The company received FDA clearance for its Nanox.ARC system and generated $2.6 million in revenue, compared to $2.2 million in Q2 2022. It also secured future supplies of chips and tubes through multiple partnership agreements and entered a collaboration with a U.S. government agency for security scanning and testing applications. The company is preparing to deploy the first Nanox.ARC in a U.S. clinical setting.
CustomersPartnersExpand
Neutral
Nanox to Report Second Quarter 2023 Financial Results on August 17, 2023
Nano-X Imaging LTD (Nanox) will report its financial results for Q2 2023 on August 17, 2023. CEO Erez Meltzer and CFO Ran Daniel will host a conference call to review the results and provide a business update. The company is focused on making diagnostic medicine more accessible and affordable globally through its proprietary medical imaging technology. The Nanox ecosystem includes the FDA-cleared Nanox.ARC, an AI-based suite of algorithms, a cloud-based infrastructure, and a proprietary decentralized marketplace that provides remote access to radiology and cardiology experts.
Management Changes
Growth-Positive
Got $2,500? Buying Shares of This Medical Device Stock Right Now Could Be a Smart Move
The article suggests that investing in medical device company Nanox could be a smart move, given the potential of its device. The companys X-ray machine is expected to have a competitive advantage in costs, which could allow it to penetrate the healthcare systems market that is often priced out of buying most other X-ray machines. However, there are uncertainties as its scans may not be reimbursable under some privatized healthcare schemes, and regulators may not agree with the FDAs recent approval of the Nanox.ARC.
Investment
growth-positive
Nanox Announces $30 Million Registered Direct Offering
Nano-X Imaging LTD has entered into a securities purchase agreement with certain institutional investors. The agreement involves the purchase and sale of over 2 million of the companys ordinary shares, along with warrants to purchase an equivalent number of shares, at a combined purchase price of $14.00 per share. The gross proceeds from the offering are expected to be approximately $30 million. The company intends to use the net proceeds for general working capital purposes, further development of its products, and the manufacture and commercial deployment of the Nanox System.
InvestmentExpand
growth-positive
Where Will Nano-X Imaging Be in 3 Years?
Nano-X Imaging, a medical device business, is predicted to be a great growth stock to own for the rest of the decade. The companys unique business model and growth story are just beginning, and it has the potential for explosive near-term growth paired with sustainable and enduring recurring cash flows for years to come.
Investment
Growth-Positive
Could Nano-X Imaging Stock Help You Become a Millionaire?
Nano-X Imaging has seen strong returns this year and is hoping for significant revenue growth with its multi-source X-ray system, the Nanox.ARC. The company believes this system will improve the accessibility of high-quality medical imaging in the U.S. and worldwide, making it a potentially good long-term investment.
CustomersExpand
growth-positive
2 Supercharged Growth Stocks That Could Make You Richer
Beam Therapeutics, a biotechnology company, is currently testing its base editing platform in early-stage trials for sickle cell disease and a form of blood cancer called acute lymphoblastic leukemia. The company is considered a speculative growth stock with the potential to deliver life-changing returns for early shareholders.
Investment
Growth-Positive
2 Red-Hot Growth Stocks That Are Still Over 300% Away From 2021 Highs
The article discusses the stock performance of Nano-X Imaging and C3.ai, both of which have more than doubled in value this year. However, it is noted that Nano-X Imaging does not generate a significant amount of revenue, with only $8.6 million over the past 12 months, and remains unprofitable.
None
Growth-Positive
Wall Street Expects Nano-X Imaging Stock to Explode by 120%, and Here's Why It Might
The article discusses the expected growth of Nano-X Imagings stock by 120% according to Wall Street. The company, which manufactures X-ray machines, has recently become a popular investment. The success of the company is largely dependent on the average usage rates of its machines.
Investment
growth-positive
Better Buy: Nano-X Imaging vs. Viking Therapeutics
The article compares Nano-X Imaging and Viking Therapeutics, two small-cap healthcare companies with potential but also risks. Nano-X Imaging is classified as growth-positive. The key theme of the article is the comparison between the two companies. The key issues discussed are customers and investment. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. The confidence level is 7.
CustomersInvestment
growth-negative
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
The article discusses the potential risks associated with owning growth stocks in the healthcare industry, specifically Nano-X Imaging, DermTech, and Viking Therapeutics. While these companies have seen significant increases in their share prices, the author believes that much of their potential has already been priced into their stocks. The key theme of the article is the need to reconsider positions in these companies due to the high level of risk involved. The structured issues mentioned in the article include the impact on customers and the need for investment. The date of the event described in the article is not provided. The confidence level of the answer is 8.
CustomersInvestment
If You'd Invested $10,000 in Nano-X Imaging in 2020, This Is How Much You Would Have Today
Why Nanox Stock Skyrocketed 191% in May
2 Medical Imaging Stocks That Are Better Buys Than Nano-X
growth-negative
Is It Too Early to Invest In Nano-X Imaging?
The article discusses the uncertainty surrounding Nano-X Imagings devices and their profitability, suggesting that it may take years to prove strong demand and achieve profitability.
Investment
growth-positive
Nano-X Imaging Ltd. (NNOX) Just Reclaimed the 20-Day Moving Average
Nano-X Imaging Ltd. (NNOX) has reached a significant support level and shows potential for growth. The stock recently broke through the 20-day moving average, indicating a short-term bullish trend. NNOX has gained 66.7% in the past four weeks and is ranked a Zacks Rank #3 (Hold). Positive earnings estimate revisions further support the bullish case for the stock. Investors are advised to watch NNOX for potential gains in the near future.
Investment
growth-positive
Why Shares of Nano-X Are Soaring Wednesday
Shares of Nano-X Imaging are up 10% after falling below $17 for the first time since May 18. The healthcare company specializes in medical imaging equipment and systems. Nano-X received FDA clearance to market Nanox.ARC, a stationary X-ray system on adults.
Customers
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
growth-positive
Q1 2023 Nano-X Imaging Ltd Earnings Call
Nano-X Imaging Ltd. has announced its Q1 2023 earnings call, highlighting its recent FDA clearance for the Nanox.ARC system. The companys CEO, Erez I. Meltzer, discussed the companys operational accomplishments, including the FDA clearance, the establishment of a U.S. demo center in Florida, and the pursuit of the European Union CE mark. The company also announced a new commercial partnership with Blackford Analysis to market the Nanox.ARC product. The company reported a GAAP net loss for Q1 2023 of $11.8 million, compared to a net loss of $21.7 million in Q1 2022.
CustomersPartnersManagement ChangesExpand
Why Nanox Stock Popped Off Another Huge Gain Today
Nano-X Imaging (NNOX) Q1 2023 Earnings Call Transcript
growth-positive
Nanox Announces First Quarter of 2023 Financial Results and Provides Business Update
Nano-X Imaging LTD announced its Q1 2023 results, reporting a net loss of $11.8 million, compared to a net loss of $21.7 million for Q1 2022. The company generated $2.4 million in revenue in Q1 2023, compared to $1.8 million in Q1 2022. The company also received FDA clearance to market its Nanox.ARC system and entered into a three-year distribution pre-sale agreement with Vital Tech SARL to deploy 270 Nanox.ARC units in Morocco. The company ended Q1 2023 with cash, cash equivalents, restricted cash and marketable securities of $91.0 million.
CustomersPartnersExpand
growth-positive
Nanox to Report First Quarter 2023 Financial Results on May 22, 2023
Nano-X Imaging LTD will report its financial results for the first quarter ended March 31, 2023. The companys CEO and CFO will host a conference call to review the results and provide a business update. Nano-X Imaging is focused on applying its proprietary medical imaging technology to make diagnostic medicine more accessible and affordable. The companys products and services aim to improve early detection and treatment, ultimately saving lives. Nanoxs ecosystem includes the Nanox.ARC system, Nanox.AI algorithms, Nanox.CLOUD infrastructure, and Nanox.MARKETPLACE teleradiology services platform.
Public Trading
The Surprising Reason Nanox Stock Jumped Again Today
Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Profit Outlook
growth-positive
Up 160% in a Month, Can Nanox Stock Keep Soaring?
Nanox stock has surged 160% in a month due to the potential of their new product. However, it is uncertain if this will lead to profitable sales.
CustomersInvestment
Up 165% in 1 Month, Is This Growth Stock Finally a Buy?
growth-negative
3 Growth Stock Warning Signs You Shouldn't Ignore
The article discusses three warning signs that investors should not ignore when it comes to growth stocks. While these signs do not always indicate disaster, being aware of them can help avoid potential problems. The specific company mentioned in the article is NNOX. The impact on the company is classified as growth-negative. The key theme of the article is warning signs for growth stocks. The key issues discussed include customers and partners. No information is provided about investors, acquisition amounts, investment amounts, layoffs, customers, partners, or the date of the event. Confidence level: 8
CustomersPartners
Nano-X Imaging Ltd. (NNOX) Is a Great Choice for 'Trend' Investors, Here's Why
growth-positive
Nanox wins FDA approval for cloud-based X-ray system
Israeli medical imaging company Nanox-X Imaging has received marketing clearance from the US FDA for its Nanox.ARC Cloud device and cloud-based infrastructure. The company plans to offer the device using an innovative pay-per-scan business model. Nanox-X Imaging had its Nasdaq IPO in August 2020 and raised $165.2 million at a company valuation of $800 million. The companys share price recently jumped 68.4% to $10.29, giving it a market cap of $567 million. Nanox-X Imaging aims to increase access to medical imaging and shift healthcare from reactive to proactive.
InvestmentPublic Trading
Why Nanox Stock Skyrocketed Today
Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging
Nanox Files 2022 Annual Report on Form 20-F
growth-positive
"Using existing data can prevent diseases and save lives" | CTech
Dr. Orit Wimpfheimer, Clinical Director at Nanox AI, discusses the potential of leveraging CT scans to extract valuable clinical findings for the identification of chronic diseases. Nanox AI uses artificial intelligence to analyze the data from CT scans and detect early signs of heart conditions, osteoporosis, and other bone diseases. The company aims to save lives by alerting radiologists to these findings and enabling early intervention. The article highlights the importance of utilizing the information contained in CT scans, which often goes unnoticed. Nanox AI has access to a large amount of CT scan data, including scans from the COVID-19 period. The companys innovative approach has the potential to revolutionize medical imaging and improve patient outcomes.
CustomersPartners
growth-positive
ננוקס תבצע באסף הרופא מחקר קליני ראשון במכשיר הרנטגן הדיגיטלי - Techtime - חדשות אלקטרוניקה והייטק
Nano-X, a company that has developed a digital X-ray device, has received approval from the Helsinki Committee to conduct human trials. The research will be conducted at Shamir Medical Center and the company expects to present the findings within the current quarter. Nano-X is also waiting for FDA approval and has begun deploying initial systems in Nigeria. The company plans to start selling the system this year, regardless of FDA approval, with the first systems being deployed in Nigeria and then in Ghana. The companys Q3 revenue was $2.4 million, compared to $2.2 million in the previous quarter.
CustomersExpand
growth-positive
Nanox to Host and Livestream 'ARC Day' event: Company's Demonstration of Nanox's Ecosystem
Nano-X Imaging LTD will be hosting its first in-person ARC Day to demonstrate its Nanox.ARC imaging system and end-to-end 3D medical imaging solution. The event aims to showcase Nanoxs goal of providing meaningful access to medical imaging. The demonstration will be followed by a live Q&A session. The companys vision is to increase early detection of medical conditions and improve access to imaging. Nanox is developing a holistic imaging solution that includes Nanox.ARC and Nanox.CLOUD, integrated with AI solutions and teleradiology services. The event will take place on November 16, 2022.
Customers
growth-positive
Nanox to Present at Two Upcoming Investor Conferences in September 2022
NANO-X IMAGING LTD announces that its management will participate in two investor conferences in September 2022. The conferences are the LifeSci Partners HealthTech Symposium and the Ladenburg Thalmann Healthcare Conference. The companys CEO and CFO will deliver presentations and host investor meetings at both events. NANO-X IMAGING is focused on applying its medical imaging technology to make diagnostic medicine more accessible and affordable. The company is developing the Nanox System, which includes the Nanox.ARC and Nanox.CLOUD, to improve imaging efficiency and reduce costs. The companys vision is to increase early detection of medical conditions and improve health outcomes.
InvestmentManagement Changes
growth-positive
ננוקס מקימה מרכז מו"פ בישראל - Techtime - חדשות אלקטרוניקה והייטק
Israeli company NanoX has announced plans to establish a development center in Israel focused on the design and development of next-generation MEMS chips and cathodes, which are the digital source for X-ray radiation in the companys imaging devices. The company is preparing to submit a marketing approval application to the FDA and has also begun the approval process in Europe. NanoX is also preparing to deploy its first X-ray systems in Africa, specifically in Nigeria and Ghana. The companys Q2 revenue amounted to $2.2 million, up from $1.8 million in the previous quarter.
CustomersPartnersExpand
growth-positive
ננוקס פועלת לקבלת אישור שיווק גם באירופה - Techtime - חדשות אלקטרוניקה והייטק
Nanox, a medical imaging company, reported revenues of $1.8 million in the first quarter of the year, compared to $1.3 million in the previous quarter. The company acquired three companies and aims to provide advanced radiology services. Nanox is awaiting FDA approval for its digital X-ray machine, which is currently the biggest obstacle for the company. The CEO announced that the company received feedback from the FDA and plans to resubmit the marketing approval request. Nanox also intends to seek marketing approval in the European Union. The companys new technology aims to revolutionize CT imaging systems, making them more portable and affordable. Nanox has signed agreements for the deployment of around 6,500 systems.
CustomersPartners
growth-positive
ננוקס פועלת לקבלת אישור שיווק גם באירופה - Techtime - חדשות אלקטרוניקה והייטק
Nanox, a medical imaging company, reported revenues of $1.8 million in the first quarter of the year, compared to $1.3 million in the previous quarter. The company acquired three companies in recent months and aims to provide advanced radiology services. Nanox is awaiting FDA approval for its digital X-ray machine, which is currently the main obstacle for commercialization. The company also plans to seek marketing approval in the European Union. Nanoxs new CT technology is expected to revolutionize the industry by offering more affordable and portable systems. The company has signed agreements for the deployment of around 6,500 systems.
CustomersInvestment
Nanox Announces FDA Clearance for HealthOST Device, an AI Software Measuring Vertebral Compression Fractures and Low Bone Density, Which are Often Associated with Osteoporosis
growth-positive
https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-704441
Israeli medical-imaging technology company Nanox has opened a semiconductor-chip fabrication plant in South Korea. The facility will produce crucial semiconductor microchips for Nanoxs 3D medical imaging system called the Nanox.ARC. The new plant aims to address supply chain issues and reduce costs compared to traditional analog X-rays. Nanox CEO Erez Meltzer stated that the facility is part of their strategy of vertical integration to expand the delivery of healthcare. The facility is located in Yongin, South Korea, near the worlds largest semiconductor cluster. Nanox Korea head Ilung Kim believes the facility will bring new technical jobs to the region. The opening ceremony was attended by the Nanox leadership team and the Ambassador of Israel to the Republic of Korea.
InvestmentExpand
growth-negative
Can medical imaging developer Nanox prove the skeptics wrong?
Israeli medical imaging company Nanox Vision, known for developing inexpensive and portable X-ray scanners, experienced a highly successful IPO in August 2020, achieving a valuation of $800 million. However, since then, the companys share price has collapsed by 84% and its market cap is now $560 million. Nanox acquired Zebra Medical Vision, an Israeli company specializing in AI systems for reading scans, for $200 million in shares. The article discusses the challenges faced by Nanox, including the skepticism surrounding its technology, the rejection of FDA approval for its second-generation device, and the lack of information about Zebra Medicals revenue. Nanoxs business model involves offering scanners on a pay-as-you-use basis and providing radiology services. The company is also facing an SEC investigation and lawsuits from investors.
Public TradingAcquisitionManagement Changes
Nanox to Introduce New Nanox.ARC Procedures, Highlight Nanox.AI Software Solutions at 2021 Radiology Society of North America Annual Meeting
growth-positive
In an up-to $200M Acquisition by Nanox, Zebra Medical Vision Brings Its AI to Reimagine Radiology Globally
Zebra Medical Vision, a deep-learning medical imaging analytics company, has announced that it will be acquired by Nanox, an innovative medical imaging company, in a deal valued at up to $200 million. The acquisition will allow Zebra Medical Vision to expand its mission of diagnosing populations at scale with its AI-based solutions. Zebra-Med will support Nanox’s medical device strategy by embedding its AI solutions into its imaging equipment, making medical imaging for diagnosis more easily accessible and affordable across the globe.
AcquisitionExpand
growth-positive
NANO-X wins FDA clearance for single-source digital x-ray
NANO-X Imaging Ltd. has received FDA clearance for its single-source Nanox.ARC digital x-ray technology. The company remains on track to commence system shipments in Q4 2021 and Q1 2022, with the goal of deploying 15,000 Nanox.ARC systems by the end of 2024. NANO-X also plans to submit an application to the FDA for its multi-source Nanox.ARC and Nanox.CLOUD in 2021. The company aims to democratize medical imaging and expand the market to those with limited access. NANO-X has a unique business model based on medical screening as a service (MSaaS) and has raised $137 million from investors including Koreas SK Telecom, Industrial Alliance, Yozma Korea, Foxconn, Fuji, and Jin Ji Full. The company had an IPO valuation of $800 million and currently has a market cap of $1.9 billion.
InvestmentPublic Trading
growth-positive
Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray
Nano-X Imaging LTD has received 510(k) clearance from the US Food and Drug Administration (FDA) for its single-source Nanox.ARC digital x-ray technology. This clearance is a significant step forward for the companys US regulatory pathway. Nano-X Imaging plans to commence system shipments in Q4 2021 and Q1 2022, with the goal of deploying 15,000 Nanox.ARC systems by the end of 2024. The company aims to democratize medical imaging and expand the market to those with limited or no access to imaging. Nano-X Imaging expects to submit a 510(k) application for its multi-source Nanox.ARC and Nanox.CLOUD in 2021. If cleared, the multi-source Nanox.ARC will be the companys commercial imaging system for global deployment.
Public Trading
growth-positive
Nanox and USARAD Introduce Radiology AI Second Opinion Program
Nano-X Imaging has extended its strategic collaboration with USARAD Holdings to launch an advanced radiology diagnostics service. The service combines over 300 expert radiologists and artificial intelligence (AI) decision support algorithms and solutions. The collaboration aims to target insurance companies, outpatient imaging centers, and other key constituents within the healthcare ecosystem in the United States. The program will offer population health screening, post-acute triage, and routine peer review and quality assurance cases. The service will utilize X-ray based algorithms and over 20 FDA 510(k)-cleared AI solutions. Nanox and USARAD have partnered with leading companies such as Zebra Medical, AIDOC, and QUREAI. The collaboration is expected to transform the quality of healthcare and decrease costs.
PartnersCustomers
growth-positive
Nanox Announces Successful Demonstration of the Nanox.ARC Prototype During RSNA 2020
Nano-X Imaging LTD, an innovative medical imaging technology company, has successfully demonstrated its next-generation x-ray prototype, the Nanox.ARC, at the 2020 Radiology Society of North America Virtual Annual Meeting. The company believes that the Nanox.ARC has the potential to significantly expand the market by providing access to medical imaging for the two-thirds of the world’s population who currently do not have access. The company has signed agreements for the deployment of more than 5,100 Nanox.ARC units through its service providers in numerous countries, and expects to begin deployments as early as mid-year 2021.
CustomersExpand
growth-positive
Nanox to Feature Nanox.ARC Digital X-Ray Technology in a Live Demonstration at the 2020 Radiology Society of North America Virtual Annual Meeting
NANO-X IMAGING LTD announced that it will host a live demonstration of its medical imaging technology at the 2020 Radiology Society of North America Virtual Annual Meeting. The demonstration will showcase the Nanox digital x-ray source tube and various imaging applications performed by the Nanox.ARC. The company will also host an investor webinar following the live event, featuring a replay of the demonstration and presentations by radiologists. The CEO of Nanox expressed excitement about the potential of their technology to revolutionize the medical imaging market. The company aims to provide affordable, early detection imaging services through collaborations with healthcare organizations. Interested parties can register for the RSNA event and the investor webinar.
InvestmentExpand
growth-positive
Nanox Signs With Ambra Health to Enable Image Access and Transfer with U.S. Hospitals and Medical imaging Providers BioSpace
NANO-X IMAGING LTD has signed an agreement with Ambra Health to facilitate the transfer of medical images between U.S. hospitals and medical imaging providers. Ambra will serve as the enterprise image exchange solution, integrated with planned U.S. Nanox.ARC system deployments via the Nanox.CLOUD infrastructure. The agreement is subject to FDA approval. Ambras network allows providers to connect with innovative imaging partners like Nanox. Nanox aims to provide seamless image exchange once their systems are approved by the FDA and deployments commence. The partnership with Ambra will enable direct connections between Nanox modalities at hospitals and imaging providers with minimal integration effort and a high level of data privacy.
Partners
growth-positive
Nano-X to unveil scan device at Chicago radiology meet
Israeli medical device company Nano-X Imaging saw its share price jump after announcing a live demonstration of its medical imaging system. The company, founded in 2012, has developed a portable CT scan device and raised $190 million in August at a valuation of $800 million. Despite attacks from short-seller investigative firms, Nano-Xs share price is now more than double its IPO value.
InvestmentPublic Trading
growth-positive
Nanox Announces Live Demonstration of its Nanox.ARC System at Radiology Society of North America (RSNA) 2020
NANO-X IMAGING LTD will demonstrate its novel technology and medical imaging system at RSNA 2020. The demonstration will include a technology section elaborating on Nanoxs first commercial-grade digital x-ray source followed by a live demonstration of the Nanox.ARC in a range of medical imaging procedures. The demonstration aims to promote preventive healthcare through early detection and improve access to medical imaging globally.
Partners
Nanox Signs Agreement With SPI Medical for the Deployment of 630 Nanox.ARC Units in Mexico
growth-positive
Nanox closes $190m IPO as valuation soars
Israeli medical imaging technology company Nanox Imaging Ltd. has closed its initial public offering, raising $190 million. The underwriters fully exercised their options to buy $34.8 million worth of shares. Since trading began, Nanoxs share price has risen over 60% to $28.90, giving the company a market cap of $1.283 billion. The company has developed a lightweight, mobile CT scanner and offers a medical screening as a service (MSaaS) model. Nanox has yet to receive FDA marketing approval.
InvestmentPublic Trading
growth-positive
Medical imaging co Nanox already worth $1.2b
Israeli medical device company Nanox Imaging Ltd. raised $165.2 million in its IPO, with a company valuation of $800 million. Despite having no revenue or FDA approval for its lightweight and mobile CT scanners, the companys share price has been soaring. Nanox has developed a system combining digital X-ray device Nanox.ARC and an AI cloud-based software Nanox.CLOUD. The companys unique medical screening as a service (MSaaS) business model allows wide distribution and accessibility.
InvestmentPublic Trading
growth-positive
After becoming Israel's newest unicorn, what's next for Nanox?
Israeli medical imaging company Nanox saw its shares surge on Nasdaq despite not earning significant revenue or receiving FDA approval for its lightweight X-ray scanners. The company raised $165.2 million in its IPO and reached a valuation of $1 billion on its first day of trading. Nanox plans to use the funds to manufacture and deliver 12,000 new devices and invest in further research and development. Its main shareholders prior to the IPO include SK Telecom, founder Ran Poliakine, and Moshe Moalem. Nanox has raised a total of $137 million and reported a loss of $13.7 million in the first six months of the year.
InvestmentPublic Trading
growth-positive
Medical imaging co Nanox raises $165.2m in Nasdaq IPO
Israeli medical imaging company Nanox has completed the largest-ever IPO of an early stage Israeli medical technology company at a valuation of $800 million. They raised $165.2 million in the IPO and have yet to receive FDA marketing approval for their lightweight mobile CT scanners. Nanox has developed a system combining digital X-ray device Nanox.ARC and an AI cloud-based software Nanox.CLOUD. The company operates on a medical screening as a service (MSaaS) business model. The IPO was underwritten by Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., Berenberg, and CIBC Capital Markets. Prior to the IPO, Nanox raised $137 million from investors including Koreas SK Telecom, Industrial Alliance, Yozma Korea, Foxconn, Fuji, and Jin Ji Full.
Public TradingInvestment
growth-positive
Israeli mini X-ray developer Nanox sets terms for $100 million Nasdaq IPO
Israeli medical imaging company Nanox plans to raise $100 million through an IPO on the Nasdaq. The company will offer 5.9 million shares at a price range of $16 to $18. Nanoxs main shareholders prior to the IPO are SK Telecom, founder Ran Poliakine, and Moshe Moalem. The funds raised will be used to manufacture and deliver 12,000 new machines and invest in further research and development. Existing investors, including SK Telecom, Yozma Group Korea, and Jin Ji Full Investment Holding Co., Ltd., have expressed interest in purchasing up to approximately $80 million of the shares. Nanox, which has raised $137 million so far, reported a loss of $13.7 million in the first six months of 2020.
InvestmentExpand
growth-positive
Medical imaging co Nanox files to raise $125m on Nasdaq
Nanox Imaging Ltd., an Israeli medical imaging technology company, has filed for a $125 million Nasdaq IPO. The company plans to disrupt early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model. The offering is expected to value the company at least $500 million. Nanox has already raised $110 million, including $59 million last week, and has signed agreements for the deployment of its Nanox.ARC medical imaging system and diagnostics services in 13 countries. The funds raised will support the deployment, which is expected to generate $300 million in service fees over the next three years. The companys unique business model allows for wide distribution and accessibility of its services.
InvestmentExpand
growth-positive
Nanox raises $110 million for medical imaging hardware
Medical imaging startup Nanox has raised $59 million in additional financing to support its global expansion. The company aims to reinvent the X-ray with its Nanox.Arc system, which uses X-ray source technology to lower the cost of imaging hardware and make it more accessible. Nanox plans to offer the system under a pay-per-scan business model and complement it with a cloud-based software called Nanox.Cloud. The company has announced contracts with several customers, including Hadassah Hospital, Gateway Group, USARAD, Promedica Bioelectronics, Distribution Partners, and Golden Vine International. Nanox hopes to onboard more than 15,000 customers within the next two years and plans to go public on the Nasdaq with a valuation of over $500 million. The recent financing round was led by A-Labs Advisory and Finance Ltd.
CustomersInvestment
Nanox Enters Asia Pacific: Signs Strategic Agreement With Golden Vine International for the Deployment of 500 Nanox.ARC Systems in Taiwan and Singapore
growth-positive
Nanox Signs $48 Million Agreement in Russia and Belarus For Nanox.ARC Medical Imaging Services
Nanox, an Israeli medical imaging technology company, has entered into exclusive distribution agreements for the introduction of its medical imaging services in Russia and Belarus. The Nanox System will offer a range of medical imaging services, from 2D X-ray to 3D Tomosynthesis computed tomography, and are aimed to be deployed in rural areas for maximum patients’ outreach. The services are planned to be operated on a pay-per-scan business model at affordable prices. The Distribution Partners will commit to Nanox a combined minimum annual service fee of approximately $48 million over a 3-year term.
PartnersExpand
Nanox Signs Agreement With Promedica Bioelectronics for the Deployment of 500 Nanox.ARC Units in Italy
N/A
SK Telecom invests $20 million in Israeli medical imaging firm Nanox
The article does not provide any specific information about the company or its activities.
Nanox Announces Agreement With CureMetrix For AI-based Assistive Diagnostic Tool to Support Nanox Cloud Platform
growth-positive
Israeli firm aims to disrupt mammograms and other X-rays
Nanox, an Israeli company, aims to revolutionize X-ray imaging with their Nanox.Arc machine. The machine is a full-body digital X-ray scanner that can perform various imaging tests. Nanox also offers Nanox.Cloud, a cloud-based repository for imaging data. The companys goal is to democratize access to medical imaging and make it more affordable. They have secured $55 million in funding and signed agreements worth $174 million for the deployment of 1,000 Nanox.Arc units. Nanox plans to receive regulatory approval in multiple countries this year and deploy the system in 2021 and 2022. The initial target markets are the United States, Asia, and developing countries with limited access to medical imaging. Nanox is a partnership between Israeli and Japanese expertise.
CustomersInvestment
growth-positive
Medical Imaging Company Nano-X Signs $174 Million Australian Distribution Agreement
Israel-based medical imaging startup Nano-X Imaging Ltd. has signed an exclusive distribution agreement with Prestons, Australia-based the Gateway Group. Gateway will distribute and operate Nano-X’s systems across Australia, New Zealand, and Norway. Gateway guarantees a minimum service fee of $58 million per year for three years. Nano-X, founded in 2012, develops a small digital X-ray imaging device, intended to reduce costs and increase accessibility to X-ray medical diagnostic results. The company has raised $55 million to date and employs a team of 60 people.
PartnersExpand
Nanox Signs Agreement With The Gateway Group for the Deployment of 1,000 Nanox.ARC Units Across Australia, New Zealand, and Norway
growth-positive
Nanox Signs Strategic Collaboration Agreement With USARAD for the Deployment of 3,000 Nanox Systems in the U.S.
NANO-X IMAGING LTD, a medical imaging technology company, has announced a partnership with Siemens Healthineers-backed USARAD. The partnership will see USARAD utilise existing radiologists and recruit additional professionals to become service providers using the Nanox.ARC and the Nanox.CLOUD for imaging diagnostics. The companies will collaborate on the deployment of 3,000 Nanox Systems in the U.S., under Nanox’s MSaaS (Medical Screening as a Service) pay-per-scan business model, which the Company expects will make medical imaging more accessible to patients at affordable costs.
PartnersExpand
growth-positive
Nanox Is Basically The High-Tech Hospital Bed From Star Trek Digital Trends
Israeli company Nanox has developed the Nanox Arc, a portable bed-like medical imaging machine that aims to make medical scanning more accessible and affordable. The device uses a silicon-based electron nano gun to produce pulsating electron beams, eliminating the need for heat and reducing the size and cost of the machine. Nanox believes that the Nanox Arc could revolutionize medical imaging and make it more readily available to people around the world. The design of the Nanox Arc is inspired by the Star Trek biobed, with a focus on patient comfort and accessibility.
CustomersPartners
growth-positive
Israeli digital X-ray co Nanox raises $26m
Israeli medical imaging company Nanox-X Imaging Ltd. has completed a $26 million financing round with participation from strategic investor Foxconn, Fujifilm, SK Telecom, and other private investors. The funds will be used to support the development, commercialization, and deployment of Nanoxs System, which includes a novel digital X-ray device and a cloud-based software. The Nanox System aims to promote early detection of medical conditions through affordable and accessible medical imaging services. Nanox plans to deploy its system in collaboration with governments, hospitals, and clinic chains, offering it under a pay-per-scan business model at lower prices than existing alternatives. The company aims to improve the accessibility and affordability of early detection services worldwide.
Investment
growth-positive
Mobile CT co Nanox plans Nasdaq IPO at $500m valuation
Israeli imaging company Nanox is planning to hold its IPO on Nasdaq in the first quarter of 2020 at a company valuation of more than $500 million. Nanox has developed a miniature version of an X-ray device that generates a 3D image and aims to provide a cheap, small, and mobile alternative to CT devices. The company has received investments from South Korean company SK Telecom and other private investors. Nanoxs target is to deploy 15,000 systems worldwide by 2022, offering affordable scans for early detection of diseases.
Public TradingInvestment
Nanox Introduces Digital X-ray Technology
growth-positive
Korean Multinational SK Telecom Invests In nanox, One Of The First Global Players To Join The nanox.vision Initiative
Nanox introduces its global 1x1x1 Initiative to provide at least one medical screening for each person on the planet each year. SK Telecom makes a strategic capital investment in nanox to commercialize its revolutionary technology. Nanox has developed a new 5D X-ray source based on advanced nano MEMS technology that creates a stable X-ray stream at a fraction of the cost. The company aims to make medical imaging accessible and affordable to all people globally. The partnership between nanox and SK Telecom is seen as a powerful example of cooperation between Korean and Israeli companies. Nanoxs technology has the potential to save millions of lives and over a trillion US dollars in cancer-associated costs. The company estimates that reaching their vision could save over 8 million people every year with regard to cancer alone.
InvestmentPartners
growth-positive
Nanox.Vision May Change Preventive Medicine Forever
Nanox.vision, an Israeli/Japanese company, has developed a revolutionary CT scanner that is portable, affordable, and uses advanced nano MEMS technology. The company has partnered with SK Telecom to democratize medical imaging and create a global consortium for preventive healthcare screening. The goal is to provide a full body scan to every person on the planet once a year. The CT scanner would be used in conjunction with advanced AI Vision technology to analyze the scans and detect anomalies. Nanox estimates that reaching this vision could save over 8 million lives and generate economic savings of over $1 trillion per year. The company plans to seed thousands of machines worldwide to change the face of healthcare. However, there are challenges in terms of storage for the large files generated by the scans.
InvestmentPartnersCustomers
Nanox Vision Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 109 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
Nanox Vision Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515942076 |
| Crunchbase | nanox-imaging |
| Phone | 97225360360 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-10-03T00:00:00.000Z |
| Created | 2020-01-17T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Aug, 2020; |